,Gene_set,Term,Overlap,P-value,Adjusted P-value,Odds Ratio,Genes,group,ordered_group,sample
0,gs_ind_0,Adrenergic signaling in cardiomyocytes,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
1,gs_ind_0,Aldosterone synthesis and secretion,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
2,gs_ind_0,Axon guidance,1/14,0.6332198153271444,0.6648808060935018,1.4983314794215796,EFNB2_EPHB4,1,1,A1
3,gs_ind_0,Bile secretion,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
4,gs_ind_0,Calcium signaling pathway,1/8,0.4318754313982918,0.5334931799625958,2.6242884250474385,GNAS_ADCY7,1,1,A1
5,gs_ind_0,Cellular senescence,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,TGFB1_TGFBR1,1,1,A1
6,gs_ind_0,Chronic myeloid leukemia,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,TGFB1_TGFBR1,1,1,A1
7,gs_ind_0,Circadian entrainment,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,GNAS_ADCY7,1,1,A1
8,gs_ind_0,Cortisol synthesis and secretion,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
9,gs_ind_0,Cushing syndrome,1/9,0.47139714051841064,0.5711157663973052,2.33786078098472,GNAS_ADCY7,1,1,A1
10,gs_ind_0,Cytokine-cytokine receptor interaction,1/22,0.799251131428496,0.799251131428496,0.9311827956989247,TGFB1_TGFBR1,1,1,A1
11,gs_ind_0,Dilated cardiomyopathy (DCM),1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
12,gs_ind_0,ECM-receptor interaction,9/101,0.1848412513418409,0.41609632200638597,1.715927750410509,COL1A1_ITGAV;COL4A1_ITGAV;COL1A1_ITGA11;COL1A2_ITGAV;COL1A1_CD44;FN1_ITGAV;COL4A3_ITGAV;FN1_ITGA4;COL1A1_ITGA1,1,1,A1
13,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/11,0.5428332428799768,0.5999735842357639,1.9144460028050492,TGFA_ERBB2,1,1,A1
14,gs_ind_0,Endocrine resistance,1/17,0.7066399913247761,0.7180374105396918,1.2248847926267281,GNAS_ADCY7,1,1,A1
15,gs_ind_0,Estrogen signaling pathway,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
16,gs_ind_0,Focal adhesion,9/110,0.282410046097811,0.4238765475236509,1.473001508295626,FN1_ITGA6;COL1A1_ITGAV;COL4A1_ITGAV;COL1A1_ITGA11;COL1A2_ITGAV;FN1_ITGAV;COL4A3_ITGAV;FN1_ITGA4;COL1A1_ITGA1,1,1,A1
17,gs_ind_0,FoxO signaling pathway,1/5,0.2960407633498514,0.4238765475236509,4.108504398826979,TGFB1_TGFBR1,1,1,A1
18,gs_ind_0,Gap junction,1/6,0.34438131178934656,0.46161750303678367,3.4615384615384617,GNAS_ADCY7,1,1,A1
19,gs_ind_0,Gastric acid secretion,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,GNAS_ADCY7,1,1,A1
20,gs_ind_0,Gastric cancer,1/11,0.5428332428799768,0.5999735842357639,1.9144460028050492,TGFB1_TGFBR1,1,1,A1
21,gs_ind_0,Glutamatergic synapse,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,GNAS_ADCY7,1,1,A1
22,gs_ind_0,GnRH signaling pathway,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
23,gs_ind_0,"Growth hormone synthesis, secretion and action",1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,GNAS_ADCY7,1,1,A1
24,gs_ind_0,Hepatitis B,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,TGFB1_TGFBR1,1,1,A1
25,gs_ind_0,Hepatocellular carcinoma,1/13,0.6051409495148683,0.6573082727489087,1.6164874551971327,TGFB1_TGFBR1,1,1,A1
26,gs_ind_0,Hippo signaling pathway,1/10,0.5083300913992203,0.5930517732990903,2.1059907834101383,TGFB1_TGFBR1,1,1,A1
27,gs_ind_0,Human T-cell leukemia virus 1 infection,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,TGFB1_TGFBR1,1,1,A1
28,gs_ind_0,Human cytomegalovirus infection,1/7,0.38959639373490884,0.5109456571619417,2.9870967741935486,GNAS_ADCY7,1,1,A1
29,gs_ind_0,Human papillomavirus infection,9/114,0.3321040276566963,0.454838124834171,1.3772925764192139,FN1_ITGA6;COL1A1_ITGAV;COL4A1_ITGAV;COL1A1_ITGA11;COL1A2_ITGAV;FN1_ITGAV;COL4A3_ITGAV;FN1_ITGA4;COL1A1_ITGA1,1,1,A1
30,gs_ind_0,Inflammatory mediator regulation of TRP channels,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
31,gs_ind_0,Insulin secretion,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
32,gs_ind_0,MAPK signaling pathway,2/26,0.5418831611846767,0.5999735842357639,1.3825634352635003,TGFB1_TGFBR1;TGFA_ERBB2,1,1,A1
33,gs_ind_0,Melanogenesis,1/8,0.4318754313982918,0.5334931799625958,2.6242884250474385,GNAS_ADCY7,1,1,A1
34,gs_ind_0,Morphine addiction,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,GNAS_ADCY7,1,1,A1
35,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.06722689075630252,0.41609632200638597,15.32258064516129,ADAM10_NOTCH2,1,1,A1
36,gs_ind_0,Non-small cell lung cancer,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,TGFA_ERBB2,1,1,A1
37,gs_ind_0,Osteoclast differentiation,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,TGFB1_TGFBR1,1,1,A1
38,gs_ind_0,Ovarian steroidogenesis,1/3,0.18916848009317436,0.41609632200638597,6.511520737327189,GNAS_ADCY7,1,1,A1
39,gs_ind_0,Oxytocin signaling pathway,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,GNAS_ADCY7,1,1,A1
40,gs_ind_0,PI3K-Akt signaling pathway,10/127,0.31087066634555205,0.43521893288377284,1.4126696832579186,FN1_ITGA6;TGFA_ERBB2;COL1A1_ITGAV;COL4A1_ITGAV;COL1A1_ITGA11;COL1A2_ITGAV;FN1_ITGAV;COL4A3_ITGAV;FN1_ITGA4;COL1A1_ITGA1,1,1,A1
41,gs_ind_0,Pancreatic cancer,1/5,0.2960407633498514,0.4238765475236509,4.108504398826979,TGFB1_TGFBR1,1,1,A1
42,gs_ind_0,Pancreatic secretion,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
43,gs_ind_0,"Parathyroid hormone synthesis, secretion and action",1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,GNAS_ADCY7,1,1,A1
44,gs_ind_0,Pathways in cancer,5/76,0.6216208498154371,0.6637646362436023,1.0159136118215402,FN1_ITGA6;COL4A1_ITGAV;FN1_ITGAV;COL4A3_ITGAV;TGFB1_TGFBR1,1,1,A1
45,gs_ind_0,Phospholipase D signaling pathway,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,GNAS_ADCY7,1,1,A1
46,gs_ind_0,Platelet activation,1/10,0.5083300913992203,0.5930517732990903,2.1059907834101383,GNAS_ADCY7,1,1,A1
47,gs_ind_0,Prostate cancer,1/5,0.2960407633498514,0.4238765475236509,4.108504398826979,TGFA_ERBB2,1,1,A1
48,gs_ind_0,Proteoglycans in cancer,2/20,0.3974021777926214,0.5109456571619417,1.8376787216148023,DCN_MET;FN1_ITGAV,1,1,A1
49,gs_ind_0,Rap1 signaling pathway,1/17,0.7066399913247761,0.7180374105396918,1.2248847926267281,GNAS_ADCY7,1,1,A1
50,gs_ind_0,Regulation of actin cytoskeleton,3/18,0.10896553003574656,0.41609632200638597,3.09009009009009,FN1_ITGA6;FN1_ITGAV;FN1_ITGA4,1,1,A1
51,gs_ind_0,Regulation of lipolysis in adipocytes,1/4,0.24437403038470287,0.41609632200638597,5.043010752688172,GNAS_ADCY7,1,1,A1
52,gs_ind_0,Relaxin signaling pathway,2/6,0.05433802115237552,0.41609632200638597,6.16710875331565,GNAS_ADCY7;TGFB1_TGFBR1,1,1,A1
53,gs_ind_0,Salivary secretion,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
54,gs_ind_0,Signaling by NOTCH,1/3,0.18916848009317436,0.41609632200638597,6.511520737327189,ADAM10_NOTCH2,1,1,A1
55,gs_ind_0,Signaling by NOTCH2,1/1,0.06722689075630252,0.41609632200638597,15.32258064516129,ADAM10_NOTCH2,1,1,A1
56,gs_ind_0,Small cell lung cancer,4/41,0.2886684365027246,0.4238765475236509,1.7132530120481928,FN1_ITGA6;COL4A1_ITGAV;FN1_ITGAV;COL4A3_ITGAV,1,1,A1
57,gs_ind_0,Th17 cell differentiation,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,TGFB1_TGFBR1,1,1,A1
58,gs_ind_0,Thermogenesis,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
59,gs_ind_0,Thyroid hormone synthesis,1/2,0.13019891500904157,0.41609632200638597,9.154838709677419,GNAS_ADCY7,1,1,A1
60,gs_ind_0,Vascular smooth muscle contraction,1/5,0.2960407633498514,0.4238765475236509,4.108504398826979,GNAS_ADCY7,1,1,A1
61,gs_ind_0,Yersinia infection,1/3,0.18916848009317436,0.41609632200638597,6.511520737327189,FN1_ITGA4,1,1,A1
62,gs_ind_0,cAMP signaling pathway,1/5,0.2960407633498514,0.4238765475236509,4.108504398826979,GNAS_ADCY7,1,1,A1
0,gs_ind_0,ECM-receptor interaction,5/101,0.05115877218138993,0.1409642706083863,4.967159277504105,FN1_ITGB6;FN1_ITGA3;LAMA5_ITGB4;COMP_ITGB1;LAMB2_ITGB4,2,2,A1
1,gs_ind_0,Focal adhesion,5/110,0.07517438407624166,0.1409642706083863,4.26395173453997,FN1_ITGB6;FN1_ITGA3;LAMA5_ITGB4;COMP_ITGB1;LAMB2_ITGB4,2,2,A1
2,gs_ind_0,Human papillomavirus infection,5/114,0.08810266913024144,0.1409642706083863,3.986899563318777,FN1_ITGB6;FN1_ITGA3;LAMA5_ITGB4;COMP_ITGB1;LAMB2_ITGB4,2,2,A1
3,gs_ind_0,MAPK signaling pathway,1/26,0.504389349379897,0.6725191325065293,2.1869639794168094,AREG_ERBB3,2,2,A1
4,gs_ind_0,PI3K-Akt signaling pathway,6/127,0.02182197026258151,0.1409642706083863,11.368627450980393,FN1_ITGB6;AREG_ERBB3;FN1_ITGA3;LAMA5_ITGB4;COMP_ITGB1;LAMB2_ITGB4,2,2,A1
5,gs_ind_0,Pathways in cancer,1/76,0.9034976720268029,0.9034976720268029,0.5793226381461676,FN1_ITGA3,2,2,A1
6,gs_ind_0,Regulation of actin cytoskeleton,2/18,0.0676856907773661,0.1409642706083863,6.621621621621622,FN1_ITGB6;FN1_ITGA3,2,2,A1
7,gs_ind_0,Small cell lung cancer,1/41,0.6826487379415633,0.7801699862189295,1.2979189485213583,FN1_ITGA3,2,2,A1
0,gs_ind_0,Adrenergic signaling in cardiomyocytes,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
1,gs_ind_0,Aldosterone synthesis and secretion,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
2,gs_ind_0,Apelin signaling pathway,1/4,0.6681674801688582,0.7467754190122533,1.3834808259587021,GNAI2_ADCY9,3,3,A1
3,gs_ind_0,Axon guidance,5/14,0.22283911510607501,0.5534921083230324,1.6220032840722496,EFNB1_EPHB3;SEMA4C_PLXNB2;EFNB1_EPHB4;SEMA4D_PLXNB2;EFNB1_EPHB6,3,3,A1
4,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,FN1_ITGB1,3,3,A1
5,gs_ind_0,Basal cell carcinoma,4/5,0.01240691524217461,0.23932209795962728,3.570943075615973,WNT7B_FZD1;WNT3A_FZD1;WNT3A_FZD2;WNT7B_FZD4,3,3,A1
6,gs_ind_0,Bile secretion,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
7,gs_ind_0,Breast cancer,7/21,0.21123877303284472,0.5534921083230324,1.502417683628828,JAG2_NOTCH1;WNT3A_FZD2;JAG2_NOTCH3;WNT7B_FZD1;WNT7B_LRP5;WNT7B_FZD4;WNT3A_FZD1,3,3,A1
8,gs_ind_0,Calcium signaling pathway,1/8,0.892274025145607,0.9041710121475485,0.7199375325351379,GNAS_ADCY9,3,3,A1
9,gs_ind_0,Chemokine signaling pathway,2/14,0.890253958107631,0.9041710121475485,0.697421559490525,CXCL14_CXCR4;GNAI2_ADCY9,3,3,A1
10,gs_ind_0,Cholinergic synapse,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAI2_ADCY9,3,3,A1
11,gs_ind_0,Circadian entrainment,2/4,0.24312357836267656,0.5534921083230324,2.3473473473473474,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
12,gs_ind_0,Cortisol synthesis and secretion,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
13,gs_ind_0,Cushing syndrome,6/9,0.006884604454375032,0.23932209795962728,3.049054675523761,GNAS_ADCY9;GNAI2_ADCY9;WNT3A_FZD2;WNT7B_FZD1;WNT7B_FZD4;WNT3A_FZD1,3,3,A1
14,gs_ind_0,Dilated cardiomyopathy (DCM),1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
15,gs_ind_0,ECM-receptor interaction,32/101,0.01259589989261196,0.23932209795962728,1.7265526900415338,TNC_SDC4;FN1_ITGB6;COL6A2_ITGB1;LAMB3_ITGB1;LAMB2_ITGB4;FN1_ITGB1;LAMA2_ITGA3;THBS1_ITGB1;LAMB3_ITGB4;COL6A1_ITGB1;COL1A2_ITGB1;FN1_ITGA3;LAMB1_ITGB4;LAMA5_ITGB1;COL1A1_ITGB1;LAMA5_ITGA3;LAMB2_ITGB1;LAMB3_ITGA2;TNC_ITGB1;LAMB3_ITGA3;COMP_ITGB1;LAMC2_ITGB1;TNC_SDC1;TNC_ITGB6;LAMA2_ITGB4;LAMA5_ITGB4;LAMC2_ITGB4;LAMC2_ITGA3;THBS1_ITGA3;TNC_ITGAV;LAMB2_ITGA3;LAMC2_ITGA2,3,3,A1
16,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/11,0.9543550297925671,0.9543550297925671,0.5252020007695267,FGF2_FGFR3,3,3,A1
17,gs_ind_0,Endocrine and other factor-regulated calcium reabsorption,1/1,0.2394957983193277,0.5534921083230324,4.20353982300885,GNAS_ADCY9,3,3,A1
18,gs_ind_0,Endocrine resistance,3/17,0.8211164037144987,0.8667339816986376,0.8128440366972477,GNAS_ADCY9;JAG2_NOTCH1;JAG2_NOTCH3,3,3,A1
19,gs_ind_0,Estrogen signaling pathway,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
20,gs_ind_0,Fibronectin matrix formation,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,FN1_ITGB1,3,3,A1
21,gs_ind_0,Focal adhesion,32/110,0.058252563493321065,0.39460321695914014,1.4821222606689735,FN1_ITGB6;TNC_ITGA2;COL6A2_ITGB1;LAMB3_ITGB1;LAMB2_ITGB4;FN1_ITGB1;LAMA2_ITGA3;THBS1_ITGB1;LAMB3_ITGB4;COL6A1_ITGB1;COL1A2_ITGB1;FN1_ITGA3;LAMB1_ITGB4;TNC_ITGA7;LAMA5_ITGB1;COL1A1_ITGB1;LAMA5_ITGA3;LAMB2_ITGB1;LAMB3_ITGA2;TNC_ITGB1;LAMB3_ITGA3;COMP_ITGB1;LAMC2_ITGB1;LAMA2_ITGB4;TNC_ITGB6;LAMA5_ITGB4;LAMC2_ITGB4;LAMC2_ITGA3;THBS1_ITGA3;TNC_ITGAV;LAMB2_ITGA3;LAMC2_ITGA2,3,3,A1
22,gs_ind_0,GABAergic synapse,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAI2_ADCY9,3,3,A1
23,gs_ind_0,Gap junction,2/6,0.4419794502542447,0.5598406369887099,1.6112266112266111,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
24,gs_ind_0,Gastric acid secretion,2/4,0.24312357836267656,0.5534921083230324,2.3473473473473474,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
25,gs_ind_0,Gastric cancer,5/11,0.09339067054763998,0.5069779258300456,2.072463768115942,WNT3A_FZD2;WNT7B_FZD1;WNT7B_LRP5;WNT7B_FZD4;WNT3A_FZD1,3,3,A1
26,gs_ind_0,Glutamatergic synapse,2/4,0.24312357836267656,0.5534921083230324,2.3473473473473474,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
27,gs_ind_0,GnRH signaling pathway,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
28,gs_ind_0,"Growth hormone synthesis, secretion and action",2/4,0.24312357836267656,0.5534921083230324,2.3473473473473474,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
29,gs_ind_0,Hepatocellular carcinoma,5/13,0.17453848464230184,0.5534921083230324,1.7499118165784833,WNT3A_FZD2;WNT7B_FZD1;WNT7B_LRP5;WNT7B_FZD4;WNT3A_FZD1,3,3,A1
30,gs_ind_0,Hippo signaling pathway,4/10,0.19602948948245072,0.5534921083230324,1.8304405874499332,WNT7B_FZD1;WNT3A_FZD1;WNT3A_FZD2;WNT7B_FZD4,3,3,A1
31,gs_ind_0,Human cytomegalovirus infection,2/7,0.5309090998409403,0.6569983747463964,1.3903903903903905,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
32,gs_ind_0,Human papillomavirus infection,37/114,0.002510996340641931,0.19083572188878678,1.9890297156246672,FN1_ITGB6;TNC_ITGA2;COL6A2_ITGB1;LAMB3_ITGB1;LAMB2_ITGB4;FN1_ITGB1;LAMA2_ITGA3;THBS1_ITGB1;LAMB3_ITGB4;COL6A1_ITGB1;COL1A2_ITGB1;FN1_ITGA3;LAMB1_ITGB4;TNC_ITGA7;LAMA5_ITGB1;COL1A1_ITGB1;LAMA5_ITGA3;LAMB2_ITGB1;LAMB3_ITGA2;TNC_ITGB1;LAMB3_ITGA3;MFNG_NOTCH1;COMP_ITGB1;WNT3A_FZD1;LAMC2_ITGB1;LAMA2_ITGB4;TNC_ITGB6;WNT3A_FZD2;LAMA5_ITGB4;LAMC2_ITGB4;LAMC2_ITGA3;THBS1_ITGA3;WNT7B_FZD1;WNT7B_FZD4;TNC_ITGAV;LAMB2_ITGA3;LAMC2_ITGA2,3,3,A1
33,gs_ind_0,Inflammatory mediator regulation of TRP channels,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
34,gs_ind_0,Insulin secretion,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
35,gs_ind_0,MAPK signaling pathway,5/26,0.7966941623090883,0.8527993850069114,0.8400718778077269,FGF6_FGFR3;AREG_ERBB3;FGF1_FGFR4;FGF6_FGFR4;FGF2_FGFR3,3,3,A1
36,gs_ind_0,Melanogenesis,5/8,0.020777814264529362,0.26318564735070527,2.8408963585434175,GNAS_ADCY9;WNT3A_FZD2;WNT7B_FZD1;WNT7B_FZD4;WNT3A_FZD1,3,3,A1
37,gs_ind_0,Morphine addiction,2/4,0.24312357836267656,0.5534921083230324,2.3473473473473474,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
38,gs_ind_0,Notch signaling pathway,3/16,0.7848568893122837,0.8521303369676223,0.8659994439810954,JAG2_NOTCH1;MFNG_NOTCH1;JAG2_NOTCH3,3,3,A1
39,gs_ind_0,Ovarian steroidogenesis,1/3,0.5619065047173127,0.6569983747463964,1.786346396965866,GNAS_ADCY9,3,3,A1
40,gs_ind_0,Oxytocin signaling pathway,2/4,0.24312357836267656,0.5534921083230324,2.3473473473473474,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
41,gs_ind_0,PI3K-Akt signaling pathway,37/127,0.03138785967408975,0.3407824764615459,1.5997130559540889,FGF6_FGFR3;FN1_ITGB6;TNC_ITGA2;COL6A2_ITGB1;LAMB3_ITGB1;LAMB2_ITGB4;FN1_ITGB1;AREG_ERBB3;LAMA2_ITGA3;THBS1_ITGB1;LAMB3_ITGB4;COL6A1_ITGB1;COL1A2_ITGB1;FN1_ITGA3;LAMB1_ITGB4;TNC_ITGA7;LAMA5_ITGB1;COL1A1_ITGB1;LAMA5_ITGA3;LAMB2_ITGB1;LAMB3_ITGA2;TNC_ITGB1;LAMB3_ITGA3;COMP_ITGB1;LAMC2_ITGB1;LAMA2_ITGB4;TNC_ITGB6;LAMA5_ITGB4;FGF1_FGFR4;LAMC2_ITGB4;LAMC2_ITGA3;THBS1_ITGA3;TNC_ITGAV;FGF6_FGFR4;LAMB2_ITGA3;FGF2_FGFR3;LAMC2_ITGA2,3,3,A1
42,gs_ind_0,Pancreatic secretion,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
43,gs_ind_0,"Parathyroid hormone synthesis, secretion and action",2/4,0.24312357836267656,0.5534921083230324,2.3473473473473474,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
44,gs_ind_0,Pathways in cancer,24/76,0.04361887940939834,0.36833720390158603,1.5535069749292751,FGF6_FGFR3;JAG2_NOTCH1;LAMB3_ITGB1;FN1_ITGB1;LAMA2_ITGA3;FN1_ITGA3;LAMA5_ITGB1;LAMB2_ITGB1;LAMA5_ITGA3;JAG2_NOTCH3;LAMB3_ITGA2;LAMB3_ITGA3;WNT3A_FZD1;LAMC2_ITGB1;WNT3A_FZD2;FGF1_FGFR4;LAMC2_ITGA3;WNT7B_LRP5;WNT7B_FZD1;WNT7B_FZD4;FGF6_FGFR4;LAMB2_ITGA3;FGF2_FGFR3;LAMC2_ITGA2,3,3,A1
45,gs_ind_0,Phospholipase D signaling pathway,1/4,0.6681674801688582,0.7467754190122533,1.3834808259587021,GNAS_ADCY9,3,3,A1
46,gs_ind_0,Platelet activation,5/10,0.0623057710988116,0.39460321695914014,2.2798185941043085,GNAS_ADCY9;COL3A1_ITGB1;GNAI2_ADCY9;COL1A1_ITGB1;COL1A2_ITGB1,3,3,A1
47,gs_ind_0,Pre-NOTCH Expression and Processing,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,MFNG_NOTCH1,3,3,A1
48,gs_ind_0,Pre-NOTCH Processing in Golgi,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,MFNG_NOTCH1,3,3,A1
49,gs_ind_0,Progesterone-mediated oocyte maturation,1/3,0.5619065047173127,0.6569983747463964,1.786346396965866,GNAI2_ADCY9,3,3,A1
50,gs_ind_0,Proteoglycans in cancer,8/20,0.07355595415360712,0.43001942428262624,1.8302537570830253,HSPG2_ITGB1;COL1A1_ITGB1;WNT3A_FZD2;WNT7B_FZD1;WNT7B_FZD4;COL1A2_ITGB1;WNT3A_FZD1;FN1_ITGB1,3,3,A1
51,gs_ind_0,Rap1 signaling pathway,5/17,0.3844914177878273,0.5534921083230324,1.3259863945578232,FGF6_FGFR3;GNAS_ADCY9;FGF1_FGFR4;FGF6_FGFR4;FGF2_FGFR3,3,3,A1
52,gs_ind_0,Ras signaling pathway,4/18,0.6658513035819371,0.7467754190122533,1.0025258903763576,FGF6_FGFR3;FGF2_FGFR3;FGF1_FGFR4;FGF6_FGFR4,3,3,A1
53,gs_ind_0,Regulation of actin cytoskeleton,7/18,0.10731532211704965,0.5437309653930515,1.7701364731067701,FGF6_FGFR3;FN1_ITGB6;FN1_ITGA3;FGF1_FGFR4;FGF6_FGFR4;FGF2_FGFR3;FN1_ITGB1,3,3,A1
54,gs_ind_0,Regulation of lipolysis in adipocytes,2/4,0.24312357836267656,0.5534921083230324,2.3473473473473474,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
55,gs_ind_0,Relaxin signaling pathway,2/6,0.4419794502542447,0.5598406369887099,1.6112266112266111,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
56,gs_ind_0,Retrograde endocannabinoid signaling,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAI2_ADCY9,3,3,A1
57,gs_ind_0,Salivary secretion,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
58,gs_ind_0,Signaling Pathways,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,FGF6_FGFR3,3,3,A1
59,gs_ind_0,Signaling by FGFR,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,FGF6_FGFR3,3,3,A1
60,gs_ind_0,Signaling by NOTCH,1/3,0.5619065047173127,0.6569983747463964,1.786346396965866,MFNG_NOTCH1,3,3,A1
61,gs_ind_0,Signaling by Receptor Tyrosine Kinases,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,FGF6_FGFR3,3,3,A1
62,gs_ind_0,Signaling pathways regulating pluripotency of stem cells,5/9,0.03814432652722226,0.36237110200861145,2.530827067669173,FGF2_FGFR3;WNT3A_FZD2;WNT7B_FZD1;WNT7B_FZD4;WNT3A_FZD1,3,3,A1
63,gs_ind_0,Small cell lung cancer,13/41,0.14099002504681693,0.5534921083230324,1.443752538242859,LAMC2_ITGB1;FN1_ITGA3;LAMA2_ITGA3;LAMA5_ITGB1;LAMB2_ITGB1;LAMA5_ITGA3;LAMB3_ITGA2;LAMB3_ITGA3;LAMC2_ITGA3;LAMB3_ITGB1;LAMB2_ITGA3;LAMC2_ITGA2;FN1_ITGB1,3,3,A1
64,gs_ind_0,TCF dependent signaling in response to WNT,2/4,0.24312357836267656,0.5534921083230324,2.3473473473473474,WNT3A_FZD1;WNT3A_FZD2,3,3,A1
65,gs_ind_0,Th1 and Th2 cell differentiation,1/7,0.8569844816588232,0.8922030220009667,0.8194690265486726,JAG2_NOTCH1,3,3,A1
66,gs_ind_0,Thermogenesis,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
67,gs_ind_0,Thyroid hormone synthesis,1/2,0.42240187214126157,0.5534921083230324,2.511504424778761,GNAS_ADCY9,3,3,A1
68,gs_ind_0,Toxoplasmosis,4/9,0.14254000212899515,0.5534921083230324,2.031972454500738,LAMB3_ITGB1;LAMC2_ITGB1;LAMA5_ITGB1;LAMB2_ITGB1,3,3,A1
69,gs_ind_0,Vascular smooth muscle contraction,1/5,0.7489984785892645,0.8249838314896246,1.1271118262268705,GNAS_ADCY9,3,3,A1
70,gs_ind_0,Vasopressin-regulated water reabsorption,1/1,0.2394957983193277,0.5534921083230324,4.20353982300885,GNAS_ADCY9,3,3,A1
71,gs_ind_0,Vibrio cholerae infection,1/1,0.2394957983193277,0.5534921083230324,4.20353982300885,GNAS_ADCY9,3,3,A1
72,gs_ind_0,Wnt signaling pathway,5/10,0.0623057710988116,0.39460321695914014,2.2798185941043085,WNT3A_FZD2;WNT7B_FZD1;WNT7B_LRP5;WNT7B_FZD4;WNT3A_FZD1,3,3,A1
73,gs_ind_0,Yersinia infection,1/3,0.5619065047173127,0.6569983747463964,1.786346396965866,FN1_ITGB1,3,3,A1
74,gs_ind_0,cAMP signaling pathway,2/5,0.34484348648723284,0.5534921083230324,1.9123669123669125,GNAS_ADCY9;GNAI2_ADCY9,3,3,A1
75,gs_ind_0,mTOR signaling pathway,5/8,0.020777814264529362,0.26318564735070527,2.8408963585434175,WNT3A_FZD2;WNT7B_FZD1;WNT7B_LRP5;WNT7B_FZD4;WNT3A_FZD1,3,3,A1
0,gs_ind_0,Adrenergic signaling in cardiomyocytes,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
1,gs_ind_0,Aldosterone synthesis and secretion,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
2,gs_ind_0,Axon guidance,2/22,0.7884176493645134,0.8013425288622923,0.8626262626262626,EFNA1_EPHA1;SEMA3C_NRP1,1,1,B1
3,gs_ind_0,Bacterial invasion of epithelial cells,1/1,0.12340425531914895,0.2067855089131685,8.228070175438596,FN1_ITGA5,1,1,B1
4,gs_ind_0,Bile secretion,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
5,gs_ind_0,Calcium signaling pathway,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
6,gs_ind_0,Chemokine signaling pathway,5/35,0.440269953384221,0.5352301394082686,1.2678930727220465,CXCL11_CXCR3;CXCL10_CXCR3;CCL5_CXCR3;CXCL13_CXCR3;CXCL9_CXCR3,1,1,B1
7,gs_ind_0,Circadian entrainment,2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
8,gs_ind_0,Cortisol synthesis and secretion,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
9,gs_ind_0,Cushing syndrome,2/6,0.16119215721594696,0.23875070541359109,3.2097902097902096,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
10,gs_ind_0,Cytokine-cytokine receptor interaction,8/51,0.27340170005691666,0.3684979435549746,1.416346805147889,CXCL11_CXCR3;IL15_IL2RG;CXCL10_CXCR3;CXCL13_CXCR3;CSF1_CSF1R;CXCL9_CXCR3;IL10_IL10RA;IL15_IL2RB,1,1,B1
11,gs_ind_0,Dilated cardiomyopathy (DCM),2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
12,gs_ind_0,ECM-receptor interaction,10/61,0.18451861307668294,0.26454612345528916,1.5278298936835522,TNC_SDC4;FN1_ITGA3;FN1_CD44;COL4A1_ITGAV;COL1A2_ITGAV;FN1_ITGAV;COL4A1_ITGA1;FN1_ITGB7;TNC_ITGAV;FN1_ITGA5,1,1,B1
13,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/8,0.657279553578801,0.6907005478285705,1.4086687306501549,EGF_ERBB3,1,1,B1
14,gs_ind_0,Endocrine and other factor-regulated calcium reabsorption,1/1,0.12340425531914895,0.2067855089131685,8.228070175438596,GNAS_ADCY9,1,1,B1
15,gs_ind_0,Endocrine resistance,2/13,0.4940256205786344,0.5672146014050987,1.4983164983164983,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
16,gs_ind_0,Estrogen signaling pathway,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
17,gs_ind_0,Fibronectin matrix formation,1/1,0.12340425531914895,0.2067855089131685,8.228070175438596,FN1_ITGA5,1,1,B1
18,gs_ind_0,Focal adhesion,9/67,0.45006769227667087,0.536619171560646,1.1568202348690153,FN1_ITGA6;FN1_ITGA3;COL4A1_ITGAV;COL1A2_ITGAV;FN1_ITGAV;COL4A1_ITGA1;FN1_ITGB7;TNC_ITGAV;FN1_ITGA5,1,1,B1
19,gs_ind_0,Gap junction,2/6,0.16119215721594696,0.23875070541359109,3.2097902097902096,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
20,gs_ind_0,Gastric acid secretion,2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
21,gs_ind_0,Glutamatergic synapse,2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
22,gs_ind_0,GnRH signaling pathway,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
23,gs_ind_0,"Growth hormone synthesis, secretion and action",2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
24,gs_ind_0,Human cytomegalovirus infection,2/9,0.30701019864612167,0.4049921769374371,2.1674641148325358,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
25,gs_ind_0,Human papillomavirus infection,9/72,0.5574174572755928,0.6063137254576624,1.0450798990748529,FN1_ITGA6;FN1_ITGA3;COL4A1_ITGAV;COL1A2_ITGAV;FN1_ITGAV;COL4A1_ITGA1;FN1_ITGB7;TNC_ITGAV;FN1_ITGA5,1,1,B1
26,gs_ind_0,Inflammatory mediator regulation of TRP channels,2/3,0.04087672592831938,0.1583973129722376,6.038961038961039,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
27,gs_ind_0,Insulin secretion,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
28,gs_ind_0,JAK-STAT signaling pathway,3/9,0.08523161210583233,0.18221930864005534,3.1489572989076464,IL15_IL2RG;IL10_IL10RA;IL15_IL2RB,1,1,B1
29,gs_ind_0,MAPK signaling pathway,4/26,0.40326052276785773,0.5000430482321436,1.39511653718091,CSF1_CSF1R;EREG_ERBB3;AREG_ERBB3;EGF_ERBB3,1,1,B1
30,gs_ind_0,Melanogenesis,2/5,0.11623427151689414,0.2067855089131685,3.809917355371901,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
31,gs_ind_0,Morphine addiction,2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
32,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.12340425531914895,0.2067855089131685,8.228070175438596,ADAM10_NOTCH2,1,1,B1
33,gs_ind_0,Osteoclast differentiation,1/5,0.48553118975911425,0.5672146014050987,2.2057416267942584,CSF1_CSF1R,1,1,B1
34,gs_ind_0,Ovarian steroidogenesis,2/3,0.04087672592831938,0.1583973129722376,6.038961038961039,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
35,gs_ind_0,Oxytocin signaling pathway,2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
36,gs_ind_0,PI3K-Akt signaling pathway,13/84,0.1877424101940762,0.26454612345528916,1.4669176976869285,FN1_ITGA6;EREG_ERBB3;AREG_ERBB3;FN1_ITGA3;COL4A1_ITGAV;EGF_ERBB3;COL1A2_ITGAV;CSF1_CSF1R;FN1_ITGAV;COL4A1_ITGA1;FN1_ITGB7;TNC_ITGAV;FN1_ITGA5,1,1,B1
37,gs_ind_0,Pancreatic secretion,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
38,gs_ind_0,"Parathyroid hormone synthesis, secretion and action",2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
39,gs_ind_0,Pathways in cancer,6/57,0.7559021499707291,0.7810988883030867,0.8586493987049029,FN1_ITGA6;IL15_IL2RG;FN1_ITGA3;COL4A1_ITGAV;FN1_ITGAV;IL15_IL2RB,1,1,B1
40,gs_ind_0,Phospholipase D signaling pathway,2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
41,gs_ind_0,Platelet activation,2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
42,gs_ind_0,Proteoglycans in cancer,3/8,0.06194486051910196,0.16714373350753592,3.53496115427303,FN1_SDC2;FN1_ITGAV;FN1_ITGA5,1,1,B1
43,gs_ind_0,Rap1 signaling pathway,3/18,0.38770096225117145,0.490560401215768,1.5527791942886282,GNAS_ADCY7;GNAS_ADCY9;CSF1_CSF1R,1,1,B1
44,gs_ind_0,Ras signaling pathway,1/16,0.8872755502332794,0.8872755502332794,0.7001594896331739,CSF1_CSF1R,1,1,B1
45,gs_ind_0,Regulation of actin cytoskeleton,5/18,0.05424273277701663,0.16714373350753592,2.6392719249862107,FN1_ITGA6;FN1_ITGA3;FN1_ITGAV;FN1_ITGB7;FN1_ITGA5,1,1,B1
46,gs_ind_0,Regulation of lipolysis in adipocytes,2/4,0.0754842667453388,0.16714373350753592,4.6767676767676765,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
47,gs_ind_0,Relaxin signaling pathway,2/6,0.16119215721594696,0.23875070541359109,3.2097902097902096,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
48,gs_ind_0,Salivary secretion,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
49,gs_ind_0,Signaling by NOTCH,1/6,0.5503989962677478,0.6063137254576624,1.8582995951417005,ADAM10_NOTCH2,1,1,B1
50,gs_ind_0,Signaling by NOTCH2,1/1,0.12340425531914895,0.2067855089131685,8.228070175438596,ADAM10_NOTCH2,1,1,B1
51,gs_ind_0,Small cell lung cancer,4/25,0.3720963865536816,0.4806244992985054,1.4567474048442905,FN1_ITGA6;COL4A1_ITGAV;FN1_ITGAV;FN1_ITGA3,1,1,B1
52,gs_ind_0,Thermogenesis,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
53,gs_ind_0,Thyroid hormone synthesis,2/2,0.014766321149299873,0.07042399317358401,8.49090909090909,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
54,gs_ind_0,Toxoplasmosis,1/8,0.657279553578801,0.6907005478285705,1.4086687306501549,IL10_IL10RA,1,1,B1
55,gs_ind_0,Tuberculosis,1/6,0.5503989962677478,0.6063137254576624,1.8582995951417005,IL10_IL10RA,1,1,B1
56,gs_ind_0,Vascular smooth muscle contraction,2/3,0.04087672592831938,0.1583973129722376,6.038961038961039,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
57,gs_ind_0,Vasopressin-regulated water reabsorption,1/1,0.12340425531914895,0.2067855089131685,8.228070175438596,GNAS_ADCY9,1,1,B1
58,gs_ind_0,Vibrio cholerae infection,1/1,0.12340425531914895,0.2067855089131685,8.228070175438596,GNAS_ADCY9,1,1,B1
59,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,6/31,0.1617343488285617,0.23875070541359109,1.795677136102668,CXCL11_CXCR3;CXCL10_CXCR3;CXCL13_CXCR3;CSF1_CSF1R;CXCL9_CXCR3;IL10_IL10RA,1,1,B1
60,gs_ind_0,Yersinia infection,1/2,0.23204218948899802,0.3197025721848417,4.91578947368421,FN1_ITGA5,1,1,B1
61,gs_ind_0,cAMP signaling pathway,2/6,0.16119215721594696,0.23875070541359109,3.2097902097902096,GNAS_ADCY7;GNAS_ADCY9,1,1,B1
0,gs_ind_0,Antigen processing and presentation,1/2,0.09972722313147844,0.3469713572580892,12.182608695652174,HLA-E_KLRD1,2,2,B1
1,gs_ind_0,Axon guidance,1/22,0.7016725379293081,0.7842222482739325,1.23768115942029,EFNB3_EPHB3,2,2,B1
2,gs_ind_0,Cytokine-cytokine receptor interaction,1/51,0.9510355202321183,0.9510355202321183,0.46728577458843396,IL34_CSF1R,2,2,B1
3,gs_ind_0,ECM-receptor interaction,4/61,0.380010383062119,0.5573229228925273,1.502152080344333,LAMB3_ITGB4;LAMB2_ITGB4;LAMB1_ITGB4;COL6A2_ITGA1,2,2,B1
4,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/8,0.3467955802829494,0.5573229228925273,3.4910485933503836,GAS6_AXL,2,2,B1
5,gs_ind_0,Epstein-Barr virus infection,1/1,0.05106382978723405,0.3469713572580892,20.391304347826086,CALR_HLA-F,2,2,B1
6,gs_ind_0,Focal adhesion,4/67,0.46209825711309,0.6271333489391936,1.3215686274509804,LAMB3_ITGB4;LAMB2_ITGB4;LAMB1_ITGB4;COL6A2_ITGA1,2,2,B1
7,gs_ind_0,Graft-versus-host disease,1/2,0.09972722313147844,0.3469713572580892,12.182608695652174,HLA-E_KLRD1,2,2,B1
8,gs_ind_0,Herpes simplex virus 1 infection,1/4,0.19026079600141488,0.40166168044743145,6.7101449275362315,CALR_HLA-F,2,2,B1
9,gs_ind_0,Human cytomegalovirus infection,1/9,0.38132621040015025,0.5573229228925273,3.1098398169336385,CALR_HLA-F,2,2,B1
10,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.14609320305603754,0.3469713572580892,8.664596273291925,CALR_HLA-F,2,2,B1
11,gs_ind_0,Human papillomavirus infection,4/72,0.5295345122762389,0.6707437155499026,1.1939148073022312,LAMB3_ITGB4;LAMB2_ITGB4;LAMB1_ITGB4;COL6A2_ITGA1,2,2,B1
12,gs_ind_0,Legionellosis,1/3,0.14609320305603754,0.3469713572580892,8.664596273291925,C3_ITGB2,2,2,B1
13,gs_ind_0,Leishmaniasis,1/2,0.09972722313147844,0.3469713572580892,12.182608695652174,C3_ITGB2,2,2,B1
14,gs_ind_0,Natural killer cell mediated cytotoxicity,1/3,0.14609320305603754,0.3469713572580892,8.664596273291925,HLA-E_KLRD1,2,2,B1
15,gs_ind_0,PI3K-Akt signaling pathway,4/84,0.6785817996635913,0.7842222482739325,0.9491820396797772,LAMB3_ITGB4;LAMB2_ITGB4;LAMB1_ITGB4;COL6A2_ITGA1,2,2,B1
16,gs_ind_0,Proteoglycans in cancer,1/8,0.3467955802829494,0.5573229228925273,3.4910485933503836,DCN_MET,2,2,B1
17,gs_ind_0,Tuberculosis,2/6,0.03206217116600524,0.3469713572580892,8.406593406593407,C3_ITGAX;C3_ITGB2,2,2,B1
18,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,1/31,0.824799541362071,0.8706217381044083,0.8467908902691511,IL34_CSF1R,2,2,B1
0,gs_ind_0,Antigen processing and presentation,2/2,0.001309328968903437,0.00981996726677578,31.133333333333333,HLA-B_KLRD1;HLA-E_KLRD1,3,3,B1
1,gs_ind_0,Axon guidance,1/22,0.5937862364510492,0.77251713550143,1.6745098039215687,SEMA4G_PLXNB2,3,3,B1
2,gs_ind_0,Chemokine signaling pathway,2/35,0.3982604714367876,0.5973907071551815,1.8826291079812207,CCL19_CCR7;CXCL14_CXCR4,3,3,B1
3,gs_ind_0,Cytokine-cytokine receptor interaction,2/51,0.618013708401144,0.77251713550143,1.1941747572815533,IL34_CSF1R;CCL19_CCR7,3,3,B1
4,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/8,0.2718545977308205,0.5626723138019765,4.72318339100346,GAS6_AXL,3,3,B1
5,gs_ind_0,Epstein-Barr virus infection,1/1,0.03829787234042553,0.19148936170212766,27.58823529411765,CALR_HLA-F,3,3,B1
6,gs_ind_0,Focal adhesion,1/67,0.9542020031633787,0.9829002687642499,0.44052287581699345,COL1A1_ITGA5,3,3,B1
7,gs_ind_0,Graft-versus-host disease,2/2,0.001309328968903437,0.00981996726677578,31.133333333333333,HLA-B_KLRD1;HLA-E_KLRD1,3,3,B1
8,gs_ind_0,Herpes simplex virus 1 infection,1/4,0.1454918424900697,0.3637296062251742,9.07843137254902,CALR_HLA-F,3,3,B1
9,gs_ind_0,Human cytomegalovirus infection,1/9,0.3007237987018453,0.5626723138019765,4.207430340557275,CALR_HLA-F,3,3,B1
10,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.11100496617800973,0.3330148985340292,11.722689075630251,CALR_HLA-F,3,3,B1
11,gs_ind_0,Human papillomavirus infection,1/72,0.965342677327954,0.9829002687642499,0.3979716024340771,COL1A1_ITGA5,3,3,B1
12,gs_ind_0,Natural killer cell mediated cytotoxicity,1/3,0.11100496617800973,0.3330148985340292,11.722689075630251,HLA-E_KLRD1,3,3,B1
13,gs_ind_0,PI3K-Akt signaling pathway,1/84,0.9829002687642499,0.9829002687642499,0.3163940132265924,COL1A1_ITGA5,3,3,B1
14,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,2/31,0.33760338828118586,0.5626723138019765,2.164021164021164,IL34_CSF1R;CCL19_CCR7,3,3,B1
0,gs_ind_0,Activated NOTCH1 Transmits Signal to the Nucleus,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
1,gs_ind_0,Adipocytokine signaling pathway,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,TNF_TNFRSF1A,4,4,B1
2,gs_ind_0,Adrenergic signaling in cardiomyocytes,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
3,gs_ind_0,Aldosterone synthesis and secretion,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
4,gs_ind_0,Amyotrophic lateral sclerosis (ALS),1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,TNF_TNFRSF1A,4,4,B1
5,gs_ind_0,Apoptosis,1/3,0.5372112135878002,0.7657422300762747,1.8979591836734695,TNF_TNFRSF1A,4,4,B1
6,gs_ind_0,Axon guidance,10/22,0.010650902599440766,0.6754981185270298,2.2904214559386973,EFNB2_EPHB4;SEMA3C_NRP1;SEMA3F_NRP1;EFNA4_EPHA2;EFNA1_EPHA2;SEMA4C_PLXNB2;SEMA3B_NRP1;EFNA3_EPHA2;EFNA1_EPHA1;EFNA4_EPHA1,4,4,B1
7,gs_ind_0,Bile secretion,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
8,gs_ind_0,Breast cancer,1/16,0.9856772841482544,0.9950646868544283,0.3800865800865801,WNT7B_LRP5,4,4,B1
9,gs_ind_0,Calcium signaling pathway,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
10,gs_ind_0,Chagas disease,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,TNF_TNFRSF1A,4,4,B1
11,gs_ind_0,Chagas disease (American trypanosomiasis),1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,TNF_TNFRSF1A,4,4,B1
12,gs_ind_0,Chemokine signaling pathway,2/35,0.999232368413863,0.999232368413863,0.2741692875700807,CXCL13_CXCR3;CXCL10_CXCR3,4,4,B1
13,gs_ind_0,Choline metabolism in cancer,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,PDGFC_PDGFRB,4,4,B1
14,gs_ind_0,Circadian entrainment,1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,GNAS_ADCY9,4,4,B1
15,gs_ind_0,Constitutive Signaling by NOTCH1 HD Domain Mutants,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
16,gs_ind_0,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
17,gs_ind_0,Constitutive Signaling by NOTCH1 PEST Domain Mutants,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
18,gs_ind_0,Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
19,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,HSP90AA1_ERBB2,4,4,B1
20,gs_ind_0,Cortisol synthesis and secretion,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
21,gs_ind_0,Cushing syndrome,1/6,0.7882607716156698,0.8613983689820721,1.0087912087912088,GNAS_ADCY9,4,4,B1
22,gs_ind_0,Cytokine-cytokine receptor interaction,8/51,0.9391651324406112,0.9813131573863993,0.6692627760588926,OSM_OSMR;IL20_IL20RA;TNF_TNFRSF1A;CXCL13_CXCR3;CXCL10_CXCR3;GDF9_BMPR2;BMP4_BMPR2;INHBB_ACVR2A,4,4,B1
23,gs_ind_0,Dilated cardiomyopathy (DCM),1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
24,gs_ind_0,ECM-receptor interaction,18/61,0.09298044370635138,0.6754981185270298,1.478644223061949,TNC_SDC4;THBS1_SDC4;COL1A2_CD44;FN1_ITGA3;COL1A1_ITGAV;FN1_CD44;TNC_SDC1;COL4A1_ITGAV;LAMA5_ITGA3;COL1A2_ITGAV;COL1A1_CD44;FN1_ITGAV;LAMA5_ITGA6;FN1_ITGB7;COL4A1_ITGA1;TNC_ITGAV;COL4A5_ITGAV;TNC_ITGA9,4,4,B1
25,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,2/8,0.5724661684442347,0.7657422300762747,1.2992575671045117,FGF2_FGFR3;PDGFC_PDGFRB,4,4,B1
26,gs_ind_0,Endocrine and other factor-regulated calcium reabsorption,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,GNAS_ADCY9,4,4,B1
27,gs_ind_0,Endocrine resistance,1/13,0.9673952520305891,0.9859990068773312,0.4708994708994709,GNAS_ADCY9,4,4,B1
28,gs_ind_0,Estrogen signaling pathway,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
29,gs_ind_0,Fluid shear stress and atherosclerosis,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,BMP4_BMPR2,4,4,B1
30,gs_ind_0,Focal adhesion,19/67,0.12145146082454723,0.6754981185270298,1.410950080515298,COL4A1_ITGAV;THBS1_ITGA6;LAMA5_ITGA6;FN1_ITGB7;COL1A1_ITGAV;COL6A1_ITGA6;COL1A2_ITGAV;FN1_ITGA6;FN1_ITGA3;PDGFC_PDGFRB;LAMA5_ITGA3;FN1_ITGAV;COL4A1_ITGA1;FN1_ITGA9;TLN1_ITGB5;COL4A2_ITGB5;TNC_ITGAV;COL4A5_ITGAV;TNC_ITGA9,4,4,B1
31,gs_ind_0,Gap junction,2/6,0.40784792062009345,0.6754981185270298,1.713965646004481,PDGFC_PDGFRB;GNAS_ADCY9,4,4,B1
32,gs_ind_0,Gastric acid secretion,1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,GNAS_ADCY9,4,4,B1
33,gs_ind_0,Gastric cancer,1/8,0.8750944565571638,0.9369698221723167,0.7647058823529411,WNT7B_LRP5,4,4,B1
34,gs_ind_0,Glutamatergic synapse,1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,GNAS_ADCY9,4,4,B1
35,gs_ind_0,GnRH signaling pathway,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
36,gs_ind_0,"Growth hormone synthesis, secretion and action",1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,GNAS_ADCY9,4,4,B1
37,gs_ind_0,Hepatitis C,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,TNF_TNFRSF1A,4,4,B1
38,gs_ind_0,Hepatocellular carcinoma,1/8,0.8750944565571638,0.9369698221723167,0.7647058823529411,WNT7B_LRP5,4,4,B1
39,gs_ind_0,Herpes simplex virus 1 infection,1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,TNF_TNFRSF1A,4,4,B1
40,gs_ind_0,Hippo signaling pathway,1/9,0.9042574248499845,0.9585128703409835,0.681203007518797,BMP4_BMPR2,4,4,B1
41,gs_ind_0,Human T-cell leukemia virus 1 infection,1/6,0.7882607716156698,0.8613983689820721,1.0087912087912088,TNF_TNFRSF1A,4,4,B1
42,gs_ind_0,Human cytomegalovirus infection,2/9,0.6417907102145972,0.7657422300762747,1.1573837506387328,TNF_TNFRSF1A;GNAS_ADCY9,4,4,B1
43,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.5372112135878002,0.7657422300762747,1.8979591836734695,TNF_TNFRSF1A,4,4,B1
44,gs_ind_0,Human papillomavirus infection,18/72,0.3311757545941169,0.6754981185270298,1.1752306945118989,FN1_ITGA6;FN1_ITGA3;COL1A1_ITGAV;FN1_ITGA9;COL4A1_ITGAV;TNF_TNFRSF1A;LAMA5_ITGA3;COL6A1_ITGA6;COL1A2_ITGAV;THBS1_ITGA6;FN1_ITGAV;LAMA5_ITGA6;FN1_ITGB7;COL4A1_ITGA1;COL4A2_ITGB5;TNC_ITGAV;COL4A5_ITGAV;TNC_ITGA9,4,4,B1
45,gs_ind_0,Inflammatory mediator regulation of TRP channels,1/3,0.5372112135878002,0.7657422300762747,1.8979591836734695,GNAS_ADCY9,4,4,B1
46,gs_ind_0,Insulin resistance,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,TNF_TNFRSF1A,4,4,B1
47,gs_ind_0,Insulin secretion,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
48,gs_ind_0,JAK-STAT signaling pathway,2/9,0.6417907102145972,0.7657422300762747,1.1573837506387328,IL20_IL20RA;OSM_OSMR,4,4,B1
49,gs_ind_0,MAPK signaling pathway,7/26,0.36389299113710694,0.6754981185270298,1.2751065124771759,AREG_ERBB3;EFNA4_EPHA2;TNF_TNFRSF1A;PDGFC_PDGFRB;EFNA1_EPHA2;EFNA3_EPHA2;FGF2_FGFR3,4,4,B1
50,gs_ind_0,Melanogenesis,1/5,0.7248586297830737,0.8261829543764065,1.1974025974025975,GNAS_ADCY9,4,4,B1
51,gs_ind_0,Melanoma,1/5,0.7248586297830737,0.8261829543764065,1.1974025974025975,PDGFC_PDGFRB,4,4,B1
52,gs_ind_0,Morphine addiction,1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,GNAS_ADCY9,4,4,B1
53,gs_ind_0,NF-kappa B signaling pathway,1/5,0.7248586297830737,0.8261829543764065,1.1974025974025975,TNF_TNFRSF1A,4,4,B1
54,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,ADAM10_NOTCH2,4,4,B1
55,gs_ind_0,Necroptosis,1/3,0.5372112135878002,0.7657422300762747,1.8979591836734695,TNF_TNFRSF1A,4,4,B1
56,gs_ind_0,Neuroactive ligand-receptor interaction,1/3,0.5372112135878002,0.7657422300762747,1.8979591836734695,EDN2_EDNRA,4,4,B1
57,gs_ind_0,Non-alcoholic fatty liver disease,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,TNF_TNFRSF1A,4,4,B1
58,gs_ind_0,Non-alcoholic fatty liver disease (NAFLD),1/1,0.225531914893617,0.6754981185270298,4.466666666666667,TNF_TNFRSF1A,4,4,B1
59,gs_ind_0,Osteoclast differentiation,1/5,0.7248586297830737,0.8261829543764065,1.1974025974025975,TNF_TNFRSF1A,4,4,B1
60,gs_ind_0,Ovarian steroidogenesis,1/3,0.5372112135878002,0.7657422300762747,1.8979591836734695,GNAS_ADCY9,4,4,B1
61,gs_ind_0,Oxytocin signaling pathway,1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,GNAS_ADCY9,4,4,B1
62,gs_ind_0,PI3K-Akt signaling pathway,24/84,0.07002370521665283,0.6754981185270298,1.4890181526426638,EFNA4_EPHA2;COL4A1_ITGAV;THBS1_ITGA6;LAMA5_ITGA6;FN1_ITGB7;AREG_ERBB3;COL1A1_ITGAV;COL6A1_ITGA6;COL1A2_ITGAV;OSM_OSMR;FN1_ITGA6;FN1_ITGA3;PDGFC_PDGFRB;EFNA1_EPHA2;LAMA5_ITGA3;FN1_ITGAV;COL4A1_ITGA1;COL4A5_ITGAV;EFNA3_EPHA2;FN1_ITGA9;COL4A2_ITGB5;TNC_ITGAV;FGF2_FGFR3;TNC_ITGA9,4,4,B1
63,gs_ind_0,Pancreatic secretion,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
64,gs_ind_0,"Parathyroid hormone synthesis, secretion and action",1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,GNAS_ADCY9,4,4,B1
65,gs_ind_0,Pathogenic Escherichia coli infection,1/3,0.5372112135878002,0.7657422300762747,1.8979591836734695,TNF_TNFRSF1A,4,4,B1
66,gs_ind_0,Pathways in cancer,9/57,0.947282380893617,0.9813131573863993,0.6627259404005862,FN1_ITGA6;FN1_ITGA3;COL4A1_ITGAV;LAMA5_ITGA3;WNT7B_LRP5;FN1_ITGAV;LAMA5_ITGA6;COL4A5_ITGAV;FGF2_FGFR3,4,4,B1
67,gs_ind_0,Phospholipase D signaling pathway,2/4,0.22004131255530113,0.6754981185270298,2.4973031283710894,PDGFC_PDGFRB;GNAS_ADCY9,4,4,B1
68,gs_ind_0,Platelet activation,1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,GNAS_ADCY9,4,4,B1
69,gs_ind_0,Prostate cancer,1/3,0.5372112135878002,0.7657422300762747,1.8979591836734695,PDGFC_PDGFRB,4,4,B1
70,gs_ind_0,Proteoglycans in cancer,2/8,0.5724661684442347,0.7657422300762747,1.2992575671045117,FN1_SDC2;FN1_ITGAV,4,4,B1
71,gs_ind_0,Rap1 signaling pathway,6/18,0.1950962181598609,0.6754981185270298,1.608819345661451,GNAS_ADCY9;EFNA4_EPHA2;PDGFC_PDGFRB;EFNA1_EPHA2;EFNA3_EPHA2;FGF2_FGFR3,4,4,B1
72,gs_ind_0,Ras signaling pathway,5/16,0.27907174770974646,0.6754981185270298,1.5085910652920962,EFNA4_EPHA2;PDGFC_PDGFRB;EFNA1_EPHA2;EFNA3_EPHA2;FGF2_FGFR3,4,4,B1
73,gs_ind_0,Regulation of actin cytoskeleton,7/18,0.08088949797201626,0.6754981185270298,1.8962510897994769,FN1_ITGA6;FN1_ITGA3;FN1_ITGA9;PDGFC_PDGFRB;FN1_ITGAV;FN1_ITGB7;FGF2_FGFR3,4,4,B1
74,gs_ind_0,Regulation of lipolysis in adipocytes,1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,GNAS_ADCY9,4,4,B1
75,gs_ind_0,Relaxin signaling pathway,1/6,0.7882607716156698,0.8613983689820721,1.0087912087912088,GNAS_ADCY9,4,4,B1
76,gs_ind_0,Renin secretion,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,EDN2_EDNRA,4,4,B1
77,gs_ind_0,Salivary secretion,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
78,gs_ind_0,Signaling by ERBB2,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,HSP90AA1_ERBB2,4,4,B1
79,gs_ind_0,Signaling by ERBB2 ECD mutants,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,HSP90AA1_ERBB2,4,4,B1
80,gs_ind_0,Signaling by ERBB2 KD Mutants,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,HSP90AA1_ERBB2,4,4,B1
81,gs_ind_0,Signaling by ERBB2 in Cancer,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,HSP90AA1_ERBB2,4,4,B1
82,gs_ind_0,Signaling by NOTCH,2/6,0.40784792062009345,0.6754981185270298,1.713965646004481,ADAM10_NOTCH1;ADAM10_NOTCH2,4,4,B1
83,gs_ind_0,Signaling by NOTCH1,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
84,gs_ind_0,Signaling by NOTCH1 HD Domain Mutants in Cancer,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
85,gs_ind_0,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
86,gs_ind_0,Signaling by NOTCH1 PEST Domain Mutants in Cancer,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
87,gs_ind_0,Signaling by NOTCH1 in Cancer,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
88,gs_ind_0,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,ADAM10_NOTCH1,4,4,B1
89,gs_ind_0,Signaling by NOTCH2,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,ADAM10_NOTCH2,4,4,B1
90,gs_ind_0,Signaling pathways regulating pluripotency of stem cells,3/9,0.3298302722479655,0.6754981185270298,1.652423137050547,FGF2_FGFR3;BMP4_BMPR2;INHBB_ACVR2A,4,4,B1
91,gs_ind_0,Small cell lung cancer,7/25,0.3209244265892701,0.6754981185270298,1.3314358001265023,FN1_ITGA6;FN1_ITGA3;COL4A1_ITGAV;LAMA5_ITGA3;FN1_ITGAV;LAMA5_ITGA6;COL4A5_ITGAV,4,4,B1
92,gs_ind_0,Sphingolipid signaling pathway,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,TNF_TNFRSF1A,4,4,B1
93,gs_ind_0,TGF-beta signaling pathway,3/7,0.19189302704181888,0.6754981185270298,2.1115511551155115,INHBB_ACVR1;BMP4_BMPR2;INHBB_ACVR2A,4,4,B1
94,gs_ind_0,TNF signaling pathway,1/3,0.5372112135878002,0.7657422300762747,1.8979591836734695,TNF_TNFRSF1A,4,4,B1
95,gs_ind_0,Thermogenesis,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
96,gs_ind_0,Thyroid hormone synthesis,1/2,0.4009456264775414,0.6754981185270298,2.6685714285714286,GNAS_ADCY9,4,4,B1
97,gs_ind_0,Toxoplasmosis,2/8,0.5724661684442347,0.7657422300762747,1.2992575671045117,TNF_TNFRSF1A;LAMA5_ITGA6,4,4,B1
98,gs_ind_0,Tuberculosis,1/6,0.7882607716156698,0.8613983689820721,1.0087912087912088,TNF_TNFRSF1A,4,4,B1
99,gs_ind_0,Vascular smooth muscle contraction,2/3,0.12841445225702372,0.6754981185270298,3.2246879334257974,GNAS_ADCY9;EDN2_EDNRA,4,4,B1
100,gs_ind_0,Vasopressin-regulated water reabsorption,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,GNAS_ADCY9,4,4,B1
101,gs_ind_0,Vibrio cholerae infection,1/1,0.225531914893617,0.6754981185270298,4.466666666666667,GNAS_ADCY9,4,4,B1
102,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,4/31,0.953540143498105,0.9813131573863993,0.5901875901875901,IL20_IL20RA;TNF_TNFRSF1A;CXCL13_CXCR3;CXCL10_CXCR3,4,4,B1
103,gs_ind_0,Wnt signaling pathway,1/4,0.6429345139319665,0.7657422300762747,1.46984126984127,WNT7B_LRP5,4,4,B1
104,gs_ind_0,cAMP signaling pathway,2/6,0.40784792062009345,0.6754981185270298,1.713965646004481,GNAS_ADCY9;EDN2_EDNRA,4,4,B1
105,gs_ind_0,mTOR signaling pathway,2/6,0.40784792062009345,0.6754981185270298,1.713965646004481,TNF_TNFRSF1A;WNT7B_LRP5,4,4,B1
0,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.014534883720930232,0.057800528849413516,76.33333333333333,HSP90AA1_ERBB2,1,1,C1
1,gs_ind_0,ECM-receptor interaction,4/116,0.04598661982110485,0.07664436636850809,5.884120171673819,TNC_SDC4;TNC_SDC1;FN1_ITGB6;TNC_ITGB6,1,1,C1
2,gs_ind_0,Focal adhesion,2/126,0.6036864506568178,0.724126792846143,1.2337662337662338,FN1_ITGB6;TNC_ITGB6,1,1,C1
3,gs_ind_0,Human papillomavirus infection,2/142,0.6863795434104436,0.724126792846143,1.0150375939849625,FN1_ITGB6;TNC_ITGB6,1,1,C1
4,gs_ind_0,PI3K-Akt signaling pathway,2/150,0.724126792846143,0.724126792846143,0.9231134314190793,FN1_ITGB6;TNC_ITGB6,1,1,C1
5,gs_ind_0,Regulation of actin cytoskeleton,1/27,0.3371444154785859,0.48163487925512277,3.8484848484848486,FN1_ITGB6,1,1,C1
6,gs_ind_0,Signaling by ERBB2,1/2,0.028900264424706758,0.057800528849413516,45.666666666666664,HSP90AA1_ERBB2,1,1,C1
7,gs_ind_0,Signaling by ERBB2 ECD mutants,1/2,0.028900264424706758,0.057800528849413516,45.666666666666664,HSP90AA1_ERBB2,1,1,C1
8,gs_ind_0,Signaling by ERBB2 KD Mutants,1/2,0.028900264424706758,0.057800528849413516,45.666666666666664,HSP90AA1_ERBB2,1,1,C1
9,gs_ind_0,Signaling by ERBB2 in Cancer,1/2,0.028900264424706758,0.057800528849413516,45.666666666666664,HSP90AA1_ERBB2,1,1,C1
0,gs_ind_0,Antigen processing and presentation,2/2,0.0004746084480303749,0.006644518272425249,52.69230769230769,HLA-B_KLRD1;HLA-E_KLRD1,2,2,C1
1,gs_ind_0,ECM-receptor interaction,3/116,0.5425756562604527,0.6905508352405761,1.2481467030823254,COL1A1_CD44;COL1A1_ITGA1;COL6A2_ITGA1,2,2,C1
2,gs_ind_0,Epstein-Barr virus infection,1/1,0.023255813953488372,0.08139534883720931,45.8,CALR_HLA-F,2,2,C1
3,gs_ind_0,Focal adhesion,2/126,0.8567537974066441,0.9288319467314359,0.6643356643356644,COL1A1_ITGA1;COL6A2_ITGA1,2,2,C1
4,gs_ind_0,Graft-versus-host disease,2/3,0.001407172416090059,0.009850206912630414,37.527472527472526,HLA-B_KLRD1;HLA-E_KLRD1,2,2,C1
5,gs_ind_0,Herpes simplex virus 1 infection,1/2,0.04603701945894637,0.10632524463613813,27.4,CALR_HLA-F,2,2,C1
6,gs_ind_0,Human cytomegalovirus infection,1/11,0.23104472380632562,0.32346261332885584,5.8,CALR_HLA-F,2,2,C1
7,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.06835194298037452,0.10632524463613813,19.514285714285716,CALR_HLA-F,2,2,C1
8,gs_ind_0,Human papillomavirus infection,2/142,0.9089798015331216,0.9288319467314359,0.5465587044534413,COL1A1_ITGA1;COL6A2_ITGA1,2,2,C1
9,gs_ind_0,Legionellosis,1/3,0.06835194298037452,0.10632524463613813,19.514285714285716,C3_ITGB2,2,2,C1
10,gs_ind_0,Leishmaniasis,1/2,0.04603701945894637,0.10632524463613813,27.4,C3_ITGB2,2,2,C1
11,gs_ind_0,Natural killer cell mediated cytotoxicity,1/3,0.06835194298037452,0.10632524463613813,19.514285714285716,HLA-E_KLRD1,2,2,C1
12,gs_ind_0,PI3K-Akt signaling pathway,2/150,0.9288319467314359,0.9288319467314359,0.4970610784564273,COL1A1_ITGA1;COL6A2_ITGA1,2,2,C1
13,gs_ind_0,Tuberculosis,2/7,0.00939662405652983,0.04385091226380588,17.307692307692307,C3_ITGAX;C3_ITGB2,2,2,C1
0,gs_ind_0,Axon guidance,1/39,0.5401037358224192,0.7330158928804644,1.9569620253164557,SEMA4C_PLXNB2,1,1,D1
1,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.018823529411764708,0.09707436182019978,56.6,HSP90AA1_ERBB2,1,1,D1
2,gs_ind_0,ECM-receptor interaction,5/123,0.04847680471811183,0.1050330768892423,3.8490456911509545,FN1_ITGB6;THBS2_CD36;TNC_ITGB6;COMP_CD36;THBS1_CD36,1,1,D1
3,gs_ind_0,Focal adhesion,3/142,0.5346947842782601,0.7330158928804644,1.2660287081339714,FN1_ITGA6;FN1_ITGB6;TNC_ITGB6,1,1,D1
4,gs_ind_0,Human papillomavirus infection,3/163,0.6510519321625233,0.7330158928804644,1.0216847372810676,FN1_ITGA6;FN1_ITGB6;TNC_ITGB6,1,1,D1
5,gs_ind_0,PI3K-Akt signaling pathway,3/168,0.6766300549665826,0.7330158928804644,0.9724844888049636,FN1_ITGA6;FN1_ITGB6;TNC_ITGB6,1,1,D1
6,gs_ind_0,Pathways in cancer,1/125,0.9400534024713315,0.9400534024713315,0.4788844621513944,FN1_ITGA6,1,1,D1
7,gs_ind_0,Regulation of actin cytoskeleton,2/31,0.10948352220635295,0.20332654124036978,4.816849816849817,FN1_ITGA6;FN1_ITGB6,1,1,D1
8,gs_ind_0,Signaling by ERBB2,1/2,0.037336293007769146,0.09707436182019978,33.88,HSP90AA1_ERBB2,1,1,D1
9,gs_ind_0,Signaling by ERBB2 ECD mutants,1/2,0.037336293007769146,0.09707436182019978,33.88,HSP90AA1_ERBB2,1,1,D1
10,gs_ind_0,Signaling by ERBB2 KD Mutants,1/2,0.037336293007769146,0.09707436182019978,33.88,HSP90AA1_ERBB2,1,1,D1
11,gs_ind_0,Signaling by ERBB2 in Cancer,1/2,0.037336293007769146,0.09707436182019978,33.88,HSP90AA1_ERBB2,1,1,D1
12,gs_ind_0,Small cell lung cancer,1/48,0.6198717253136414,0.7330158928804644,1.556701030927835,FN1_ITGA6,1,1,D1
0,gs_ind_0,ECM-receptor interaction,1/123,0.7465114911777372,0.8675233367770102,1.0497397339502603,FN1_ITGB7,2,2,D1
1,gs_ind_0,Epstein-Barr virus infection,1/1,0.009411764705882354,0.05647058823529413,121.28571428571429,CALR_HLA-F,2,2,D1
2,gs_ind_0,Focal adhesion,1/142,0.8047943920481544,0.8675233367770102,0.8526315789473684,FN1_ITGB7,2,2,D1
3,gs_ind_0,Herpes simplex virus 1 infection,1/5,0.04639604164062271,0.09279208328124541,32.76623376623377,CALR_HLA-F,2,2,D1
4,gs_ind_0,Human cytomegalovirus infection,1/10,0.09115860308708787,0.15627189100643635,16.959183673469386,CALR_HLA-F,2,2,D1
5,gs_ind_0,Human immunodeficiency virus 1 infection,1/4,0.037248761464513586,0.0893970275148326,40.142857142857146,CALR_HLA-F,2,2,D1
6,gs_ind_0,Human papillomavirus infection,1/163,0.8568447414315734,0.8675233367770102,0.6880733944954128,FN1_ITGB7,2,2,D1
7,gs_ind_0,Legionellosis,1/3,0.02803583095221228,0.08410749285663684,51.734693877551024,C3_ITGB2,2,2,D1
8,gs_ind_0,Leishmaniasis,1/2,0.018756936736958933,0.07502774694783573,72.6,C3_ITGB2,2,2,D1
9,gs_ind_0,PI3K-Akt signaling pathway,1/168,0.8675233367770102,0.8675233367770102,0.6549385332768122,FN1_ITGB7,2,2,D1
10,gs_ind_0,Regulation of actin cytoskeleton,1/31,0.2621909268310626,0.3932863902465939,5.36734693877551,FN1_ITGB7,2,2,D1
11,gs_ind_0,Tuberculosis,2/7,0.001376484383833842,0.016517812606006106,55.8,C3_ITGB2;C3_ITGAX,2,2,D1
0,gs_ind_0,Axon guidance,3/14,0.13092564663748374,0.2909458814166305,2.823088455772114,EFNB2_EPHB4;EFNA1_EPHA1;SEMA4C_PLXNB2,1,1,F1
1,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.09459459459459461,0.2364864864864865,10.925925925925926,HSP90AA1_ERBB2,1,1,F1
2,gs_ind_0,ECM-receptor interaction,7/50,0.1468402033124219,0.2936804066248438,1.9504950495049505,FN1_ITGB6;COL1A2_CD44;FN1_ITGA3;FN1_CD44;TNC_ITGB6;COL1A1_CD44;THBS1_SDC1,1,1,F1
3,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/6,0.45507555433157704,0.6067674057754361,2.4358974358974357,TGFA_ERBB2,1,1,F1
4,gs_ind_0,Focal adhesion,3/50,0.9118885429741139,0.9917338042226895,0.5936289281102023,TNC_ITGB6;FN1_ITGB6;FN1_ITGA3,1,1,F1
5,gs_ind_0,Human papillomavirus infection,3/55,0.9472445223756961,0.9917338042226895,0.5127301214257736,TNC_ITGB6;FN1_ITGB6;FN1_ITGA3,1,1,F1
6,gs_ind_0,MAPK signaling pathway,2/12,0.31656806651795993,0.48702779464301527,2.184,AREG_ERBB3;TGFA_ERBB2,1,1,F1
7,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.09459459459459461,0.2364864864864865,10.925925925925926,ADAM10_NOTCH2,1,1,F1
8,gs_ind_0,Non-small cell lung cancer,1/1,0.09459459459459461,0.2364864864864865,10.925925925925926,TGFA_ERBB2,1,1,F1
9,gs_ind_0,PI3K-Akt signaling pathway,5/57,0.690966012869595,0.8637075160869937,0.9212814645308924,FN1_ITGB6;AREG_ERBB3;FN1_ITGA3;TGFA_ERBB2;TNC_ITGB6,1,1,F1
10,gs_ind_0,Pathways in cancer,1/41,0.9917338042226895,0.9917338042226895,0.2878179384203481,FN1_ITGA3,1,1,F1
11,gs_ind_0,Prostate cancer,1/3,0.25937483471730044,0.4715906085769099,4.619047619047619,TGFA_ERBB2,1,1,F1
12,gs_ind_0,Regulation of actin cytoskeleton,2/12,0.31656806651795993,0.48702779464301527,2.184,FN1_ITGB6;FN1_ITGA3,1,1,F1
13,gs_ind_0,Signaling by ERBB2,1/1,0.09459459459459461,0.2364864864864865,10.925925925925926,HSP90AA1_ERBB2,1,1,F1
14,gs_ind_0,Signaling by ERBB2 ECD mutants,1/1,0.09459459459459461,0.2364864864864865,10.925925925925926,HSP90AA1_ERBB2,1,1,F1
15,gs_ind_0,Signaling by ERBB2 KD Mutants,1/1,0.09459459459459461,0.2364864864864865,10.925925925925926,HSP90AA1_ERBB2,1,1,F1
16,gs_ind_0,Signaling by ERBB2 in Cancer,1/1,0.09459459459459461,0.2364864864864865,10.925925925925926,HSP90AA1_ERBB2,1,1,F1
17,gs_ind_0,Signaling by NOTCH,1/6,0.45507555433157704,0.6067674057754361,2.4358974358974357,ADAM10_NOTCH2,1,1,F1
18,gs_ind_0,Signaling by NOTCH2,1/1,0.09459459459459461,0.2364864864864865,10.925925925925926,ADAM10_NOTCH2,1,1,F1
19,gs_ind_0,Small cell lung cancer,1/16,0.8138977250280803,0.9575267353271534,0.8922558922558923,FN1_ITGA3,1,1,F1
0,gs_ind_0,Bacterial invasion of epithelial cells,1/1,0.02702702702702703,0.05405405405405406,42.142857142857146,FN1_ITGA5,2,2,F1
1,gs_ind_0,ECM-receptor interaction,1/50,0.8117683105873942,0.8117683105873942,0.8359264497878359,FN1_ITGA5,2,2,F1
2,gs_ind_0,Fibronectin matrix formation,1/1,0.02702702702702703,0.05405405405405406,42.142857142857146,FN1_ITGA5,2,2,F1
3,gs_ind_0,Focal adhesion,2/50,0.4154910697187504,0.5453401428838368,1.9504950495049505,COL1A1_ITGA5;FN1_ITGA5,2,2,F1
4,gs_ind_0,Human papillomavirus infection,2/55,0.4759485175167745,0.5453401428838368,1.6846846846846846,COL1A1_ITGA5;FN1_ITGA5,2,2,F1
5,gs_ind_0,Legionellosis,1/1,0.02702702702702703,0.05405405405405406,42.142857142857146,C3_ITGB2,2,2,F1
6,gs_ind_0,Leishmaniasis,1/1,0.02702702702702703,0.05405405405405406,42.142857142857146,C3_ITGB2,2,2,F1
7,gs_ind_0,PI3K-Akt signaling pathway,2/57,0.49989513097685034,0.5453401428838368,1.5913043478260869,COL1A1_ITGA5;FN1_ITGA5,2,2,F1
8,gs_ind_0,Proteoglycans in cancer,1/4,0.10482884724061592,0.1797065952696273,13.761904761904763,FN1_ITGA5,2,2,F1
9,gs_ind_0,Regulation of actin cytoskeleton,1/12,0.28955705148430716,0.43433557722646077,4.68,FN1_ITGA5,2,2,F1
10,gs_ind_0,Tuberculosis,2/3,0.0016396043793304067,0.01967525255196488,41.57142857142857,C3_ITGB2;C3_ITGAX,2,2,F1
11,gs_ind_0,Yersinia infection,1/1,0.02702702702702703,0.05405405405405406,42.142857142857146,FN1_ITGA5,2,2,F1
0,gs_ind_0,Apelin signaling pathway,1/1,0.14864864864864868,0.44594594594594605,6.8604651162790695,JAG1_NOTCH3,3,3,F1
1,gs_ind_0,Axon guidance,1/14,0.9063372951412046,0.99535847364035,0.6471531676022454,EFNB3_EPHB4,3,3,F1
2,gs_ind_0,Bacterial invasion of epithelial cells,1/1,0.14864864864864868,0.44594594594594605,6.8604651162790695,FN1_ITGA5,3,3,F1
3,gs_ind_0,Breast cancer,2/18,0.7901107991237156,0.99535847364035,0.8602504943968359,JAG1_NOTCH3;JAG2_NOTCH3,3,3,F1
4,gs_ind_0,Chemokine signaling pathway,6/21,0.06433699874361438,0.44594594594594605,2.33615221987315,CCL5_CXCR3;CXCL12_CXCR3;CXCL9_CXCR3;CCL11_CXCR3;CCL21_CXCR3;CCL19_CXCR3,3,3,F1
5,gs_ind_0,Cytokine-cytokine receptor interaction,6/30,0.2665900003198559,0.719793000863611,1.5305514157973175,TNFSF14_LTBR;IL16_CD4;IL34_CSF1R;CSF1_CSF1R;CXCL9_CXCR3;LTB_LTBR,3,3,F1
6,gs_ind_0,ECM-receptor interaction,3/50,0.9949189536835078,0.99535847364035,0.3500888550393501,COL1A1_ITGA11;LAMB2_ITGB4;FN1_ITGA5,3,3,F1
7,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/6,0.6261011598163226,0.99535847364035,1.5295169946332736,GAS6_AXL,3,3,F1
8,gs_ind_0,Endocrine resistance,2/16,0.7274731666952254,0.99535847364035,0.9793052475979305,JAG1_NOTCH3;JAG2_NOTCH3,3,3,F1
9,gs_ind_0,Fibronectin matrix formation,1/1,0.14864864864864868,0.44594594594594605,6.8604651162790695,FN1_ITGA5,3,3,F1
10,gs_ind_0,Focal adhesion,5/50,0.9277915099509741,0.99535847364035,0.613012729844413,COL1A1_ITGA5;COL1A1_ITGA11;COL4A2_ITGB5;FN1_ITGA5;LAMB2_ITGB4,3,3,F1
11,gs_ind_0,Human papillomavirus infection,6/55,0.9017684827431545,0.99535847364035,0.6636636636636637,COL1A1_ITGA5;JAG1_NOTCH3;COL1A1_ITGA11;COL4A2_ITGB5;FN1_ITGA5;LAMB2_ITGB4,3,3,F1
12,gs_ind_0,Legionellosis,1/1,0.14864864864864868,0.44594594594594605,6.8604651162790695,C3_ITGB2,3,3,F1
13,gs_ind_0,Leishmaniasis,1/1,0.14864864864864868,0.44594594594594605,6.8604651162790695,C3_ITGB2,3,3,F1
14,gs_ind_0,MAPK signaling pathway,1/12,0.8665077424928208,0.99535847364035,0.761860465116279,CSF1_CSF1R,3,3,F1
15,gs_ind_0,NF-kappa B signaling pathway,2/4,0.1052848516240108,0.44594594594594605,3.915989159891599,TNFSF14_LTBR;LTB_LTBR,3,3,F1
16,gs_ind_0,Notch signaling pathway,2/20,0.8404108972321574,0.99535847364035,0.7644259369422962,JAG1_NOTCH3;JAG2_NOTCH3,3,3,F1
17,gs_ind_0,Osteoclast differentiation,1/3,0.38514835775109757,0.8665838049399696,2.9003322259136213,CSF1_CSF1R,3,3,F1
18,gs_ind_0,PI3K-Akt signaling pathway,6/57,0.9235862234485321,0.99535847364035,0.6268774703557313,COL1A1_ITGA5;COL1A1_ITGA11;CSF1_CSF1R;COL4A2_ITGB5;FN1_ITGA5;LAMB2_ITGB4,3,3,F1
19,gs_ind_0,Pathways in cancer,2/41,0.99535847364035,0.99535847364035,0.3158977372906259,JAG1_NOTCH3;JAG2_NOTCH3,3,3,F1
20,gs_ind_0,Proteoglycans in cancer,1/4,0.4784361931267931,0.9936751703402626,2.24031007751938,FN1_ITGA5,3,3,F1
21,gs_ind_0,Rap1 signaling pathway,1/7,0.6840291491405543,0.99535847364035,1.3162790697674418,CSF1_CSF1R,3,3,F1
22,gs_ind_0,Ras signaling pathway,1/7,0.6840291491405543,0.99535847364035,1.3162790697674418,CSF1_CSF1R,3,3,F1
23,gs_ind_0,Regulation of actin cytoskeleton,1/12,0.8665077424928208,0.99535847364035,0.761860465116279,FN1_ITGA5,3,3,F1
24,gs_ind_0,Tuberculosis,2/3,0.057888612683133236,0.44594594594594605,5.069686411149826,C3_ITGB2;C3_ITGAX,3,3,F1
25,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,4/20,0.34221893986855606,0.8399919433137285,1.5247198417930126,TNFSF14_LTBR;CSF1_CSF1R;IL34_CSF1R;CXCL9_CXCR3,3,3,F1
26,gs_ind_0,Yersinia infection,1/1,0.14864864864864868,0.44594594594594605,6.8604651162790695,FN1_ITGA5,3,3,F1
0,gs_ind_0,AGE-RAGE signaling pathway in diabetic complications,1/3,0.2828327000342405,0.6128041834075211,4.13317191283293,TGFB1_TGFBR2,1,1,G2
1,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.19846007650885703,0.483746436490339,5.806779661016949,FN1_ITGA5,1,1,G2
2,gs_ind_0,Cellular senescence,1/4,0.35858980918555317,0.6398757335191428,3.2033898305084745,TGFB1_TGFBR2,1,1,G2
3,gs_ind_0,Chemokine signaling pathway,2/7,0.15934852489324564,0.483746436490339,3.280701754385965,CCL19_CCR10;CXCL14_CXCR4,1,1,G2
4,gs_ind_0,Chronic myeloid leukemia,1/4,0.35858980918555317,0.6398757335191428,3.2033898305084745,TGFB1_TGFBR2,1,1,G2
5,gs_ind_0,Cytokine-cytokine receptor interaction,2/36,0.9168160699630024,0.9444108284590952,0.604422013938957,CSF1_CSF1R;TGFB1_TGFBR2,1,1,G2
6,gs_ind_0,ECM-receptor interaction,19/119,0.009198250523579575,0.17936588520980173,2.3909405130070946,LAMA2_ITGA1;COL4A1_ITGAV;COL1A1_ITGA11;FN1_ITGB7;COL6A1_ITGA1;COL1A2_ITGA1;COL1A1_ITGAV;COL6A3_ITGA1;COL1A2_ITGAV;FN1_ITGA5;COL6A2_ITGA1;LAMA4_ITGAV;FN1_ITGA3;COL4A1_ITGA1;FN1_ITGAV;THBS1_SDC1;LAMB1_ITGAV;COL1A1_ITGA1;COL1A2_ITGA11,1,1,G2
7,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/10,0.6746335405013638,0.8762088172296704,1.3438256658595642,GAS6_AXL,1,1,G2
8,gs_ind_0,Epstein-Barr virus infection,1/1,0.10452961672473868,0.4529616724738676,9.711864406779661,CALR_HLA-F,1,1,G2
9,gs_ind_0,Fibronectin matrix formation,1/2,0.19846007650885703,0.483746436490339,5.806779661016949,FN1_ITGA5,1,1,G2
10,gs_ind_0,Focal adhesion,21/127,0.002482329724051234,0.09681085923799813,2.848916408668731,LAMA2_ITGA1;COL4A1_ITGAV;COL1A1_ITGA11;FN1_ITGB7;COL6A1_ITGA1;COL1A2_ITGA1;COL1A1_ITGAV;COL6A3_ITGA1;COL1A2_ITGAV;FN1_ITGA5;COL6A2_ITGA1;LAMA4_ITGAV;FN1_ITGA3;COL4A1_ITGA1;FN1_ITGAV;LAMB1_ITGAV;COL1A1_ITGA5;TLN1_ITGB5;COL4A2_ITGB5;COL1A1_ITGA1;COL1A2_ITGA11,1,1,G2
11,gs_ind_0,FoxO signaling pathway,1/5,0.4265838223460952,0.6398757335191428,2.6117103235747305,TGFB1_TGFBR2,1,1,G2
12,gs_ind_0,Gastric cancer,1/12,0.741407460732798,0.8762088172296704,1.120677966101695,TGFB1_TGFBR2,1,1,G2
13,gs_ind_0,Hepatitis B,1/4,0.35858980918555317,0.6398757335191428,3.2033898305084745,TGFB1_TGFBR2,1,1,G2
14,gs_ind_0,Hepatocellular carcinoma,1/11,0.7098717852124073,0.8762088172296704,1.2225497420781135,TGFB1_TGFBR2,1,1,G2
15,gs_ind_0,Herpes simplex virus 1 infection,1/2,0.19846007650885703,0.483746436490339,5.806779661016949,CALR_HLA-F,1,1,G2
16,gs_ind_0,Hippo signaling pathway,1/16,0.8375279226607955,0.9444108284590952,0.8366718027734977,TGFB1_TGFBR2,1,1,G2
17,gs_ind_0,Human T-cell leukemia virus 1 infection,1/5,0.4265838223460952,0.6398757335191428,2.6117103235747305,TGFB1_TGFBR2,1,1,G2
18,gs_ind_0,Human cytomegalovirus infection,1/5,0.4265838223460952,0.6398757335191428,2.6117103235747305,CALR_HLA-F,1,1,G2
19,gs_ind_0,Human immunodeficiency virus 1 infection,1/2,0.19846007650885703,0.483746436490339,5.806779661016949,CALR_HLA-F,1,1,G2
20,gs_ind_0,Human papillomavirus infection,20/133,0.015010937224411615,0.19514218391735097,2.2594970572498663,LAMA2_ITGA1;COL4A1_ITGAV;COL1A1_ITGA11;FN1_ITGB7;COL6A1_ITGA1;COL1A2_ITGA1;COL1A1_ITGAV;COL6A3_ITGA1;COL1A2_ITGAV;FN1_ITGA5;COL6A2_ITGA1;LAMA4_ITGAV;FN1_ITGA3;COL4A1_ITGA1;FN1_ITGAV;LAMB1_ITGAV;COL1A1_ITGA5;COL4A2_ITGB5;COL1A1_ITGA1;COL1A2_ITGA11,1,1,G2
21,gs_ind_0,Legionellosis,1/1,0.10452961672473868,0.4529616724738676,9.711864406779661,C3_ITGB2,1,1,G2
22,gs_ind_0,Leishmaniasis,1/1,0.10452961672473868,0.4529616724738676,9.711864406779661,C3_ITGB2,1,1,G2
23,gs_ind_0,MAPK signaling pathway,2/32,0.8768131755487827,0.9444108284590952,0.689608636977058,CSF1_CSF1R;TGFB1_TGFBR2,1,1,G2
24,gs_ind_0,Osteoclast differentiation,2/5,0.0866137565433848,0.4529616724738676,4.505582137161085,CSF1_CSF1R;TGFB1_TGFBR2,1,1,G2
25,gs_ind_0,PI3K-Akt signaling pathway,21/147,0.022806905755127775,0.22236733111249582,2.1557537912578058,LAMA2_ITGA1;COL4A1_ITGAV;COL1A1_ITGA11;FN1_ITGB7;COL6A1_ITGA1;COL1A2_ITGA1;COL1A1_ITGAV;COL6A3_ITGA1;COL1A2_ITGAV;FN1_ITGA5;COL6A2_ITGA1;LAMA4_ITGAV;FN1_ITGA3;CSF1_CSF1R;COL4A1_ITGA1;FN1_ITGAV;LAMB1_ITGAV;COL1A1_ITGA5;COL4A2_ITGB5;COL1A1_ITGA1;COL1A2_ITGA11,1,1,G2
26,gs_ind_0,Pancreatic cancer,1/5,0.4265838223460952,0.6398757335191428,2.6117103235747305,TGFB1_TGFBR2,1,1,G2
27,gs_ind_0,Pathways in cancer,6/99,0.9792640835990645,0.9792640835990645,0.5026151163983181,LAMB1_ITGAV;LAMA4_ITGAV;FN1_ITGA3;COL4A1_ITGAV;TGFB1_TGFBR2;FN1_ITGAV,1,1,G2
28,gs_ind_0,Proteoglycans in cancer,2/20,0.6431967446147733,0.8762088172296704,1.1446298673513051,FN1_ITGAV;FN1_ITGA5,1,1,G2
29,gs_ind_0,Rap1 signaling pathway,1/21,0.9100504839270462,0.9444108284590952,0.6302719747733544,CSF1_CSF1R,1,1,G2
30,gs_ind_0,Ras signaling pathway,1/22,0.9201951661909132,0.9444108284590952,0.6,CSF1_CSF1R,1,1,G2
31,gs_ind_0,Regulation of actin cytoskeleton,4/26,0.2815440868193347,0.6128041834075211,1.675685297258811,FN1_ITGAV;FN1_ITGA3;FN1_ITGB7;FN1_ITGA5,1,1,G2
32,gs_ind_0,Relaxin signaling pathway,1/5,0.4265838223460952,0.6398757335191428,2.6117103235747305,TGFB1_TGFBR2,1,1,G2
33,gs_ind_0,Small cell lung cancer,5/55,0.7206209061133725,0.8762088172296704,0.9035506094329624,LAMB1_ITGAV;LAMA4_ITGAV;FN1_ITGA3;COL4A1_ITGAV;FN1_ITGAV,1,1,G2
34,gs_ind_0,TGF-beta signaling pathway,1/12,0.741407460732798,0.8762088172296704,1.120677966101695,TGFB1_TGFBR2,1,1,G2
35,gs_ind_0,Th17 cell differentiation,1/2,0.19846007650885703,0.483746436490339,5.806779661016949,TGFB1_TGFBR2,1,1,G2
36,gs_ind_0,Tuberculosis,2/3,0.029714829458090047,0.23177566977310238,7.130325814536341,C3_ITGB2;C3_ITGAX,1,1,G2
37,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,1/8,0.5913318867140623,0.854146058586979,1.6719840478564307,CSF1_CSF1R,1,1,G2
38,gs_ind_0,Yersinia infection,1/2,0.19846007650885703,0.483746436490339,5.806779661016949,FN1_ITGA5,1,1,G2
0,gs_ind_0,Activated NOTCH1 Transmits Signal to the Nucleus,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
1,gs_ind_0,Axon guidance,4/20,0.2979878631093144,0.42295051538096234,1.6087537587704643,BMP7_BMPR2;NTN1_UNC5C;SEMA4D_PLXNB2;SEMA4C_PLXNB2,2,2,G2
2,gs_ind_0,Constitutive Signaling by NOTCH1 HD Domain Mutants,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
3,gs_ind_0,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
4,gs_ind_0,Constitutive Signaling by NOTCH1 PEST Domain Mutants,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
5,gs_ind_0,Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
6,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.13937282229965156,0.38095238095238093,7.253164556962025,HSP90AA1_ERBB2,2,2,G2
7,gs_ind_0,Cytokine-cytokine receptor interaction,1/36,0.9969545928369856,0.9991942950973834,0.26166117565458646,BMP7_BMPR2,2,2,G2
8,gs_ind_0,ECM-receptor interaction,23/119,0.020979857122853718,0.38095238095238093,1.8934847579199043,TNC_SDC4;COL6A2_ITGB1;COL4A1_ITGB8;LAMA5_ITGA6;LAMB3_ITGA6;LAMB2_ITGB4;THBS1_SDC4;FN1_ITGB8;THBS1_CD36;LAMB3_ITGB4;COL9A3_ITGB1;LAMB1_ITGB4;CHAD_ITGA2;LAMA5_ITGB1;LAMA5_ITGA3;TNC_ITGB1;LAMB3_ITGA3;TNC_SDC1;TNC_ITGB6;LAMA5_ITGB4;LAMC2_ITGB4;CHAD_ITGB1;COL1A1_CD44,2,2,G2
9,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,2/10,0.41776749133283425,0.5744303005826471,1.7161410018552876,TGFA_ERBB3;TGFA_ERBB2,2,2,G2
10,gs_ind_0,Epstein-Barr virus infection,1/1,0.13937282229965156,0.38095238095238093,7.253164556962025,CALR_HLA-F,2,2,G2
11,gs_ind_0,Focal adhesion,21/127,0.1682875633318418,0.38095238095238093,1.3879336349924585,COL6A2_ITGB1;COL4A1_ITGB8;THBS1_ITGA6;LAMA5_ITGA6;LAMB3_ITGA6;LAMB2_ITGB4;FN1_ITGB8;COL6A1_ITGA6;LAMB3_ITGB4;FN1_ITGA6;COL9A3_ITGB1;LAMB1_ITGB4;CHAD_ITGA2;LAMA5_ITGB1;LAMA5_ITGA3;TNC_ITGB1;LAMB3_ITGA3;TNC_ITGB6;LAMA5_ITGB4;LAMC2_ITGB4;CHAD_ITGB1,2,2,G2
12,gs_ind_0,Herpes simplex virus 1 infection,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,CALR_HLA-F,2,2,G2
13,gs_ind_0,Hippo signaling pathway,1/16,0.915581614026779,0.9591807385042446,0.6248561565017261,BMP7_BMPR2,2,2,G2
14,gs_ind_0,Human cytomegalovirus infection,1/5,0.5305420702822784,0.6484403081227846,1.9505178365937859,CALR_HLA-F,2,2,G2
15,gs_ind_0,Human immunodeficiency virus 1 infection,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,CALR_HLA-F,2,2,G2
16,gs_ind_0,Human papillomavirus infection,21/133,0.2507452985768467,0.38095238095238093,1.2760011524056467,COL6A2_ITGB1;COL4A1_ITGB8;THBS1_ITGA6;LAMA5_ITGA6;LAMB3_ITGA6;LAMB2_ITGB4;FN1_ITGB8;COL6A1_ITGA6;LAMB3_ITGB4;FN1_ITGA6;COL9A3_ITGB1;LAMB1_ITGB4;CHAD_ITGA2;LAMA5_ITGB1;LAMA5_ITGA3;TNC_ITGB1;LAMB3_ITGA3;TNC_ITGB6;LAMA5_ITGB4;LAMC2_ITGB4;CHAD_ITGB1,2,2,G2
17,gs_ind_0,MAPK signaling pathway,4/32,0.6839765059818911,0.8133774665730596,0.9692307692307692,EREG_ERBB3;TGFA_ERBB3;AREG_ERBB3;TGFA_ERBB2,2,2,G2
18,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.13937282229965156,0.38095238095238093,7.253164556962025,ADAM10_NOTCH2,2,2,G2
19,gs_ind_0,Non-small cell lung cancer,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,TGFA_ERBB2,2,2,G2
20,gs_ind_0,PI3K-Akt signaling pathway,25/147,0.08522870730973417,0.38095238095238093,1.5670858392564242,EREG_ERBB3;COL6A2_ITGB1;COL4A1_ITGB8;THBS1_ITGA6;LAMA5_ITGA6;LAMB3_ITGA6;LAMB2_ITGB4;AREG_ERBB3;FN1_ITGB8;COL6A1_ITGA6;LAMB3_ITGB4;FN1_ITGA6;COL9A3_ITGB1;LAMB1_ITGB4;CHAD_ITGA2;LAMA5_ITGB1;LAMA5_ITGA3;TNC_ITGB1;LAMB3_ITGA3;TGFA_ERBB2;TNC_ITGB6;LAMA5_ITGB4;LAMC2_ITGB4;CHAD_ITGB1;TGFA_ERBB3,2,2,G2
21,gs_ind_0,Pathways in cancer,6/99,0.9991942950973834,0.9991942950973834,0.3569295754132984,FN1_ITGA6;LAMA5_ITGB1;LAMA5_ITGA3;LAMB3_ITGA3;LAMA5_ITGA6;LAMB3_ITGA6,2,2,G2
22,gs_ind_0,Programmed Cell Death,1/1,0.13937282229965156,0.38095238095238093,7.253164556962025,TNFSF10_RIPK1,2,2,G2
23,gs_ind_0,Prostate cancer,1/5,0.5305420702822784,0.6484403081227846,1.9505178365937859,TGFA_ERBB2,2,2,G2
24,gs_ind_0,RIPK1-mediated regulated necrosis,1/1,0.13937282229965156,0.38095238095238093,7.253164556962025,TNFSF10_RIPK1,2,2,G2
25,gs_ind_0,Regulated Necrosis,1/1,0.13937282229965156,0.38095238095238093,7.253164556962025,TNFSF10_RIPK1,2,2,G2
26,gs_ind_0,Regulation of actin cytoskeleton,2/26,0.905646856731027,0.9591807385042446,0.640774320019603,FN1_ITGA6;FN1_ITGB8,2,2,G2
27,gs_ind_0,Signaling by ERBB2,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,HSP90AA1_ERBB2,2,2,G2
28,gs_ind_0,Signaling by ERBB2 ECD mutants,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,HSP90AA1_ERBB2,2,2,G2
29,gs_ind_0,Signaling by ERBB2 KD Mutants,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,HSP90AA1_ERBB2,2,2,G2
30,gs_ind_0,Signaling by ERBB2 in Cancer,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,HSP90AA1_ERBB2,2,2,G2
31,gs_ind_0,Signaling by NOTCH,2/7,0.2530451692957044,0.38095238095238093,2.4285714285714284,ADAM10_NOTCH1;ADAM10_NOTCH2,2,2,G2
32,gs_ind_0,Signaling by NOTCH1,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
33,gs_ind_0,Signaling by NOTCH1 HD Domain Mutants in Cancer,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
34,gs_ind_0,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
35,gs_ind_0,Signaling by NOTCH1 PEST Domain Mutants in Cancer,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
36,gs_ind_0,Signaling by NOTCH1 in Cancer,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
37,gs_ind_0,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.2597402597402597,0.38095238095238093,4.336708860759494,ADAM10_NOTCH1,2,2,G2
38,gs_ind_0,Signaling by NOTCH2,1/1,0.13937282229965156,0.38095238095238093,7.253164556962025,ADAM10_NOTCH2,2,2,G2
39,gs_ind_0,Small cell lung cancer,6/55,0.8248556848001839,0.9252098674355125,0.7892675283979632,FN1_ITGA6;LAMA5_ITGB1;LAMA5_ITGA3;LAMB3_ITGA3;LAMA5_ITGA6;LAMB3_ITGA6,2,2,G2
40,gs_ind_0,TCF dependent signaling in response to WNT,1/4,0.45326504481434066,0.6043533930857875,2.392405063291139,DKK1_LRP5,2,2,G2
41,gs_ind_0,TGF-beta signaling pathway,1/12,0.8410998794868295,0.9252098674355125,0.8369620253164557,BMP7_BMPR2,2,2,G2
42,gs_ind_0,Toxoplasmosis,3/19,0.5103420691238002,0.6484403081227846,1.2851282051282051,LAMB3_ITGA6;LAMA5_ITGB1;LAMA5_ITGA6,2,2,G2
43,gs_ind_0,Wnt signaling pathway,1/10,0.7828035469235338,0.9064041069640918,1.003616636528029,DKK1_LRP5,2,2,G2
0,gs_ind_0,Apoptosis,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,TNFSF10_TNFRSF10B,3,3,G2
1,gs_ind_0,Axon guidance,3/20,0.8302122562032386,0.9998865312263325,0.7942735949098622,SEMA3F_NRP1;SEMA3C_NRP1;SEMA4C_PLXNB2,3,3,G2
2,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,FN1_ITGB1,3,3,G2
3,gs_ind_0,Cytokine-cytokine receptor interaction,1/36,0.9998865312263325,0.9998865312263325,0.1737078393001036,TNFSF10_TNFRSF10B,3,3,G2
4,gs_ind_0,ECM-receptor interaction,43/119,1.068600785535934e-07,3.419522513714989e-06,3.504961147638972,COL6A3_ITGB1;TNC_SDC4;COL6A1_ITGA2;FN1_ITGB6;COL4A5_ITGB1;COL6A2_ITGB1;COL1A2_ITGA2;COL4A1_ITGB1;SPP1_ITGB5;LAMB3_ITGB1;FN1_ITGB1;LAMC1_ITGB1;THBS1_ITGB1;FN1_CD44;COL6A2_ITGA2;THBS2_ITGB1;THBS1_CD36;SPP1_ITGB1;COL4A6_ITGA1;LAMC1_ITGA2;SPP1_ITGAV;COL1A2_ITGB1;COL6A1_ITGB1;THBS2_CD36;LAMA5_ITGB1;LAMB2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;COL6A3_ITGA2;COL1A1_ITGB1;COL4A1_ITGA2;COL4A5_ITGA2;COL4A6_ITGAV;COMP_ITGB1;COL4A6_ITGB1;TNC_SDC1;TNC_ITGB6;COL1A1_ITGA2;COL4A6_ITGA2;TNC_ITGAV;LAMA5_ITGA2;COL4A5_ITGAV;LAMC2_ITGA2,3,3,G2
5,gs_ind_0,Fibronectin matrix formation,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,FN1_ITGB1,3,3,G2
6,gs_ind_0,Focal adhesion,43/127,1.426281772279477e-06,2.2820508356471632e-05,3.129075630252101,COL6A3_ITGB1;COL6A1_ITGA2;FN1_ITGB6;FN1_ITGA2;COL4A5_ITGB1;TNC_ITGA2;COL6A2_ITGB1;VEGFA_EGFR;COL1A2_ITGA2;COL4A1_ITGB1;SPP1_ITGB5;LAMB3_ITGB1;FN1_ITGB1;LAMC1_ITGB1;THBS1_ITGB1;COL6A2_ITGA2;THBS2_ITGB1;LAMC1_ITGA2;SPP1_ITGB1;COL4A6_ITGA1;COL6A1_ITGB1;SPP1_ITGAV;COL1A2_ITGB1;FN1_ITGA6;LAMA5_ITGB1;LAMB2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;COL6A3_ITGA2;COL1A1_ITGB1;COL4A1_ITGA2;COL4A5_ITGA2;COL4A6_ITGAV;COMP_ITGB1;COL4A6_ITGB1;TNC_ITGB6;COL1A1_ITGA2;COL4A6_ITGA2;TNC_ITGA5;TNC_ITGAV;LAMA5_ITGA2;COL4A5_ITGAV;LAMC2_ITGA2,3,3,G2
7,gs_ind_0,Human papillomavirus infection,42/133,3.039262056046586e-05,0.0003241879526449692,2.658669905860917,COL6A3_ITGB1;COL6A1_ITGA2;FN1_ITGB6;FN1_ITGA2;COL4A5_ITGB1;TNC_ITGA2;COL6A2_ITGB1;COL1A2_ITGA2;COL4A1_ITGB1;SPP1_ITGB5;LAMB3_ITGB1;FN1_ITGB1;LAMC1_ITGB1;THBS1_ITGB1;COL6A2_ITGA2;THBS2_ITGB1;LAMC1_ITGA2;SPP1_ITGB1;COL4A6_ITGA1;COL6A1_ITGB1;SPP1_ITGAV;COL1A2_ITGB1;FN1_ITGA6;LAMA5_ITGB1;LAMB2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;COL6A3_ITGA2;COL1A1_ITGB1;COL4A1_ITGA2;COL4A5_ITGA2;COL4A6_ITGAV;COMP_ITGB1;COL4A6_ITGB1;TNC_ITGB6;COL1A1_ITGA2;COL4A6_ITGA2;TNC_ITGA5;TNC_ITGAV;LAMA5_ITGA2;COL4A5_ITGAV;LAMC2_ITGA2,3,3,G2
8,gs_ind_0,Influenza A,1/1,0.20905923344947736,0.5714146480697004,4.815126050420168,TNFSF10_TNFRSF10B,3,3,G2
9,gs_ind_0,MAPK signaling pathway,1/32,0.9996657461323475,0.9998865312263325,0.19819004524886877,VEGFA_EGFR,3,3,G2
10,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.20905923344947736,0.5714146480697004,4.815126050420168,ADAM10_NOTCH2,3,3,G2
11,gs_ind_0,Natural killer cell mediated cytotoxicity,1/1,0.20905923344947736,0.5714146480697004,4.815126050420168,TNFSF10_TNFRSF10B,3,3,G2
12,gs_ind_0,Necroptosis,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,TNFSF10_TNFRSF10B,3,3,G2
13,gs_ind_0,PI3K-Akt signaling pathway,43/147,0.00027011384288916753,0.0021609107431133402,2.3677481840193706,COL6A3_ITGB1;COL6A1_ITGA2;FN1_ITGB6;FN1_ITGA2;COL4A5_ITGB1;TNC_ITGA2;COL6A2_ITGB1;VEGFA_EGFR;COL1A2_ITGA2;COL4A1_ITGB1;SPP1_ITGB5;LAMB3_ITGB1;FN1_ITGB1;LAMC1_ITGB1;THBS1_ITGB1;COL6A2_ITGA2;THBS2_ITGB1;LAMC1_ITGA2;SPP1_ITGB1;COL4A6_ITGA1;COL6A1_ITGB1;SPP1_ITGAV;COL1A2_ITGB1;FN1_ITGA6;LAMA5_ITGB1;LAMB2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;COL6A3_ITGA2;COL1A1_ITGB1;COL4A1_ITGA2;COL4A5_ITGA2;COL4A6_ITGAV;COMP_ITGB1;COL4A6_ITGB1;TNC_ITGB6;COL1A1_ITGA2;COL4A6_ITGA2;TNC_ITGA5;TNC_ITGAV;LAMA5_ITGA2;COL4A5_ITGAV;LAMC2_ITGA2,3,3,G2
14,gs_ind_0,Pathogenic Escherichia coli infection,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,TNFSF10_TNFRSF10B,3,3,G2
15,gs_ind_0,Pathways in cancer,19/99,0.7470802166698334,0.9998865312263325,0.8901737603681056,FN1_ITGA2;COL4A5_ITGB1;COL4A1_ITGB1;LAMB3_ITGB1;FN1_ITGB1;LAMC1_ITGB1;LAMC1_ITGA2;FN1_ITGA6;LAMA5_ITGB1;LAMB2_ITGB1;LAMB3_ITGA2;COL4A5_ITGA2;COL4A1_ITGA2;COL4A5_ITGAV;COL4A6_ITGAV;COL4A6_ITGB1;COL4A6_ITGA2;LAMA5_ITGA2;LAMC2_ITGA2,3,3,G2
16,gs_ind_0,Platelet activation,6/8,0.0013283961085833937,0.00850173509493372,3.9217485159201297,COL3A1_ITGB1;COL1A1_ITGA2;COL1A1_ITGB1;COL1A2_ITGA2;COL3A1_ITGA2;COL1A2_ITGB1,3,3,G2
17,gs_ind_0,Proteoglycans in cancer,9/20,0.010525772560900924,0.048117817421261366,2.407056594837793,HSPG2_ITGB1;FN1_SDC2;FN1_ITGA2;COL1A1_ITGA2;COL1A2_ITGA2;COL1A1_ITGB1;COL1A2_ITGB1;HSPG2_ITGA2;FN1_ITGB1,3,3,G2
18,gs_ind_0,Rap1 signaling pathway,1/21,0.9940815762201101,0.9998865312263325,0.3124877858119992,VEGFA_EGFR,3,3,G2
19,gs_ind_0,Ras signaling pathway,1/22,0.9954165590276041,0.9998865312263325,0.29747899159663865,VEGFA_EGFR,3,3,G2
20,gs_ind_0,Regulation of actin cytoskeleton,4/26,0.8359811408754032,0.9998865312263325,0.7859408916346635,FN1_ITGA6;FN1_ITGB6;FN1_ITGA2;FN1_ITGB1,3,3,G2
21,gs_ind_0,Signaling by ERBB2,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,HSP90AA1_EGFR,3,3,G2
22,gs_ind_0,Signaling by ERBB2 ECD mutants,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,HSP90AA1_EGFR,3,3,G2
23,gs_ind_0,Signaling by ERBB2 KD Mutants,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,HSP90AA1_EGFR,3,3,G2
24,gs_ind_0,Signaling by ERBB2 in Cancer,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,HSP90AA1_EGFR,3,3,G2
25,gs_ind_0,Signaling by NOTCH,1/7,0.8101275517499901,0.9998865312263325,0.9428571428571428,ADAM10_NOTCH2,3,3,G2
26,gs_ind_0,Signaling by NOTCH2,1/1,0.20905923344947736,0.5714146480697004,4.815126050420168,ADAM10_NOTCH2,3,3,G2
27,gs_ind_0,Small cell lung cancer,19/55,0.006385652163648123,0.03405681153945666,1.96841419732986,FN1_ITGA2;COL4A5_ITGB1;COL4A1_ITGB1;LAMB3_ITGB1;FN1_ITGB1;LAMC1_ITGB1;LAMC1_ITGA2;FN1_ITGA6;LAMA5_ITGB1;COL4A5_ITGA2;LAMB2_ITGB1;LAMB3_ITGA2;COL4A1_ITGA2;COL4A5_ITGAV;COL4A6_ITGAV;COL4A6_ITGB1;COL4A6_ITGA2;LAMA5_ITGA2;LAMC2_ITGA2,3,3,G2
28,gs_ind_0,Toxoplasmosis,4/19,0.5895403566705495,0.8575132460662538,1.0966643975493533,LAMB3_ITGB1;LAMA5_ITGB1;LAMC1_ITGB1;LAMB2_ITGB1,3,3,G2
29,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,1/8,0.8508145049464209,0.9998865312263325,0.828966880869995,TNFSF10_TNFRSF10B,3,3,G2
30,gs_ind_0,Wnt signaling pathway,1/10,0.9081713480203195,0.9998865312263325,0.6662665066026411,SFRP1_FZD6,3,3,G2
31,gs_ind_0,Yersinia infection,1/2,0.3749908627957409,0.5714146480697004,2.8789915966386554,FN1_ITGB1,3,3,G2
0,gs_ind_0,Axon guidance,1/12,0.6348852643627918,0.9457215971364836,1.4928,EFNB3_EPHB3,1,1,H1
1,gs_ind_0,Cell adhesion molecules,1/2,0.1500613231368588,0.4501839694105764,7.944,ICAM2_ITGAM,1,1,H1
2,gs_ind_0,Cell adhesion molecules (CAMs),1/2,0.1500613231368588,0.4501839694105764,7.944,ICAM2_ITGAM,1,1,H1
3,gs_ind_0,Cell cycle,1/1,0.0778443113772455,0.3002566295979469,13.32,TGFB1_SMAD3,1,1,H1
4,gs_ind_0,Chemokine signaling pathway,2/16,0.3602550141346352,0.6191319621896073,1.9960474308300395,CCL19_CCR10;CCL19_CXCR3,1,1,H1
5,gs_ind_0,Cytokine-cytokine receptor interaction,1/29,0.9244942013415238,0.9900846511465794,0.5633898305084746,CSF1_CSF1R,1,1,H1
6,gs_ind_0,ECM-receptor interaction,3/61,0.9156892734226033,0.9900846511465794,0.5772357723577236,LAMB2_ITGA3;LAMB2_ITGB4;THBS1_SDC1,1,1,H1
7,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/3,0.21702618858668202,0.4507466993723396,5.64,GAS6_AXL,1,1,H1
8,gs_ind_0,Epstein-Barr virus infection,1/1,0.0778443113772455,0.3002566295979469,13.32,CALR_HLA-F,1,1,H1
9,gs_ind_0,Focal adhesion,2/60,0.9786512548491291,0.9900846511465794,0.38627380524613725,LAMB2_ITGA3;LAMB2_ITGB4,1,1,H1
10,gs_ind_0,Herpes simplex virus 1 infection,1/3,0.21702618858668202,0.4507466993723396,5.64,CALR_HLA-F,1,1,H1
11,gs_ind_0,Human cytomegalovirus infection,1/4,0.2790911858328597,0.5382472869633723,4.36,CALR_HLA-F,1,1,H1
12,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.21702618858668202,0.4507466993723396,5.64,CALR_HLA-F,1,1,H1
13,gs_ind_0,Human papillomavirus infection,2/67,0.9900846511465794,0.9900846511465794,0.32367149758454106,LAMB2_ITGA3;LAMB2_ITGB4,1,1,H1
14,gs_ind_0,Inflammatory bowel disease,1/1,0.0778443113772455,0.3002566295979469,13.32,TGFB1_SMAD3,1,1,H1
15,gs_ind_0,Inflammatory bowel disease (IBD),1/1,0.0778443113772455,0.3002566295979469,13.32,TGFB1_SMAD3,1,1,H1
16,gs_ind_0,Legionellosis,2/2,0.005627299617632205,0.07596854483803477,14.391304347826088,C3_ITGAM;C3_ITGB2,1,1,H1
17,gs_ind_0,Leishmaniasis,2/2,0.005627299617632205,0.07596854483803477,14.391304347826088,C3_ITGAM;C3_ITGB2,1,1,H1
18,gs_ind_0,MAPK signaling pathway,1/13,0.6655077905775255,0.9457215971364836,1.3733333333333333,CSF1_CSF1R,1,1,H1
19,gs_ind_0,Osteoclast differentiation,1/3,0.21702618858668202,0.4507466993723396,5.64,CSF1_CSF1R,1,1,H1
20,gs_ind_0,PI3K-Akt signaling pathway,3/68,0.954422894471643,0.9900846511465794,0.48418491484184917,CSF1_CSF1R;LAMB2_ITGA3;LAMB2_ITGB4,1,1,H1
21,gs_ind_0,Pathways in cancer,1/41,0.9781526722553862,0.9900846511465794,0.36578313253012046,LAMB2_ITGA3,1,1,H1
22,gs_ind_0,Rap1 signaling pathway,1/6,0.38982382804530835,0.6191319621896073,2.9815384615384617,CSF1_CSF1R,1,1,H1
23,gs_ind_0,Ras signaling pathway,1/6,0.38982382804530835,0.6191319621896073,2.9815384615384617,CSF1_CSF1R,1,1,H1
24,gs_ind_0,Small cell lung cancer,1/18,0.7860936568015839,0.9900846511465794,0.9697297297297297,LAMB2_ITGA3,1,1,H1
25,gs_ind_0,Tuberculosis,2/4,0.030831196848149132,0.2774807716333422,7.898550724637682,C3_ITGAM;C3_ITGB2,1,1,H1
26,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,1/19,0.8047566263423853,0.9900846511465794,0.9138461538461539,CSF1_CSF1R,1,1,H1
0,gs_ind_0,Activated NOTCH1 Transmits Signal to the Nucleus,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
1,gs_ind_0,Axon guidance,6/12,0.04917321105583642,0.6802106630113267,2.215342465753425,EFNB2_EPHB4;EFNB2_EPHB6;EFNB2_EPHB3;EFNB1_EPHB4;CXCL12_CXCR4;EFNB3_EPHB3,2,2,H1
2,gs_ind_0,Breast cancer,8/16,0.021896817195491358,0.6802106630113267,2.262187088274045,JAG2_NOTCH2;JAG1_NOTCH2;JAG2_NOTCH1;FGF1_FGFR1;JAG2_NOTCH3;WNT7B_LRP5;JAG2_NOTCH4;JAG1_NOTCH4,2,2,H1
3,gs_ind_0,Cell adhesion molecules,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,JAM3_ITGB2,2,2,H1
4,gs_ind_0,Cell adhesion molecules (CAMs),1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,JAM3_ITGB2,2,2,H1
5,gs_ind_0,Chemokine signaling pathway,3/16,0.8201995479568516,0.9038933793810201,0.8135788262370541,CCL28_CCR10;CXCL12_CXCR4;CCL19_CCR10,2,2,H1
6,gs_ind_0,Constitutive Signaling by NOTCH1 HD Domain Mutants,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
7,gs_ind_0,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
8,gs_ind_0,Constitutive Signaling by NOTCH1 PEST Domain Mutants,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
9,gs_ind_0,Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
10,gs_ind_0,Cytokine-cytokine receptor interaction,5/29,0.9098161189943949,0.9453687450549767,0.6885875706214689,CCL28_CCR10;CTF1_IL6ST;IL34_CSF1R;CSF1_CSF1R;CXCL12_CXCR4,2,2,H1
11,gs_ind_0,ECM-receptor interaction,15/61,0.6192950912205422,0.827929245561451,0.9760532150776053,LAMB1_ITGAV;THBS1_SDC4;COL1A2_CD44;LAMB1_ITGA6;LAMB1_ITGB4;LAMA5_ITGB4;LAMC2_ITGB4;COL1A2_ITGAV;COL1A1_CD44;LAMB3_ITGB4;LAMC1_ITGB4;LAMA4_ITGA6;LAMC1_ITGAV;LAMB2_ITGB4;THBS1_SDC1,2,2,H1
12,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/3,0.5831994280879643,0.827929245561451,1.6987951807228916,GAS6_AXL,2,2,H1
13,gs_ind_0,Endocrine resistance,6/12,0.04917321105583642,0.6802106630113267,2.215342465753425,JAG2_NOTCH2;JAG1_NOTCH2;JAG2_NOTCH1;JAG2_NOTCH3;JAG2_NOTCH4;JAG1_NOTCH4,2,2,H1
14,gs_ind_0,Focal adhesion,12/60,0.9103550878307183,0.9453687450549767,0.7282211082509145,LAMB1_ITGAV;LAMB1_ITGA6;LAMB1_ITGB4;VEGFA_EGFR;LAMA5_ITGB4;LAMC2_ITGB4;COL1A2_ITGAV;LAMB3_ITGB4;LAMC1_ITGB4;LAMA4_ITGA6;LAMC1_ITGAV;LAMB2_ITGB4,2,2,H1
15,gs_ind_0,Gastric cancer,1/4,0.6899410379678759,0.827929245561451,1.3132530120481927,WNT7B_LRP5,2,2,H1
16,gs_ind_0,Hepatocellular carcinoma,1/4,0.6899410379678759,0.827929245561451,1.3132530120481927,WNT7B_LRP5,2,2,H1
17,gs_ind_0,Human cytomegalovirus infection,1/4,0.6899410379678759,0.827929245561451,1.3132530120481927,CXCL12_CXCR4,2,2,H1
18,gs_ind_0,Human papillomavirus infection,13/67,0.9446873575486882,0.9497910619400144,0.6813559322033899,LAMB1_ITGAV;JAG1_NOTCH4;LAMB1_ITGA6;JAG1_NOTCH2;LAMB1_ITGB4;LAMA5_ITGB4;LAMC2_ITGB4;COL1A2_ITGAV;LAMB3_ITGB4;LAMC1_ITGB4;LAMA4_ITGA6;LAMC1_ITGAV;LAMB2_ITGB4,2,2,H1
19,gs_ind_0,Intestinal immune network for IgA production,2/2,0.062116730394632426,0.6802106630113267,4.08641975308642,CCL28_CCR10;CXCL12_CXCR4,2,2,H1
20,gs_ind_0,JAK-STAT signaling pathway,1/4,0.6899410379678759,0.827929245561451,1.3132530120481927,CTF1_IL6ST,2,2,H1
21,gs_ind_0,Leukocyte transendothelial migration,2/3,0.1562329885683179,0.6802106630113267,2.9012345679012346,CXCL12_CXCR4;JAM3_ITGB2,2,2,H1
22,gs_ind_0,MAPK signaling pathway,3/13,0.6814433293311459,0.827929245561451,1.0140646976090013,CSF1_CSF1R;VEGFA_EGFR;FGF1_FGFR1,2,2,H1
23,gs_ind_0,Melanoma,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,FGF1_FGFR1,2,2,H1
24,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.25149700598802394,0.6802106630113267,4.0120481927710845,ADAM10_NOTCH2,2,2,H1
25,gs_ind_0,NOTCH4 Activation and Transmission of Signal to the Nucleus,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,JAG1_NOTCH4,2,2,H1
26,gs_ind_0,Notch signaling pathway,6/16,0.1831127871327675,0.6802106630113267,1.6351183063511832,JAG2_NOTCH2;JAG1_NOTCH2;JAG2_NOTCH1;JAG2_NOTCH3;JAG2_NOTCH4;JAG1_NOTCH4,2,2,H1
27,gs_ind_0,Osteoclast differentiation,1/3,0.5831994280879643,0.827929245561451,1.6987951807228916,CSF1_CSF1R,2,2,H1
28,gs_ind_0,PI3K-Akt signaling pathway,14/68,0.905357041254505,0.9453687450549767,0.7390190805480855,LAMB1_ITGAV;LAMB1_ITGA6;LAMB1_ITGB4;VEGFA_EGFR;FGF1_FGFR1;LAMA5_ITGB4;LAMC2_ITGB4;COL1A2_ITGAV;CSF1_CSF1R;LAMB3_ITGB4;LAMC1_ITGB4;LAMA4_ITGA6;LAMC1_ITGAV;LAMB2_ITGB4,2,2,H1
29,gs_ind_0,Pathways in cancer,13/41,0.18136087402500803,0.6802106630113267,1.3949356749030017,LAMB1_ITGAV;JAG1_NOTCH4;JAG2_NOTCH2;LAMB1_ITGA6;JAG1_NOTCH2;JAG2_NOTCH1;FGF1_FGFR1;JAG2_NOTCH3;WNT7B_LRP5;CXCL12_CXCR4;JAG2_NOTCH4;LAMA4_ITGA6;LAMC1_ITGAV,2,2,H1
30,gs_ind_0,Proteoglycans in cancer,1/10,0.9497910619400144,0.9497910619400144,0.5421686746987951,DCN_EGFR,2,2,H1
31,gs_ind_0,Rap1 signaling pathway,3/6,0.16817401392563283,0.6802106630113267,2.201557935735151,CSF1_CSF1R;VEGFA_EGFR;FGF1_FGFR1,2,2,H1
32,gs_ind_0,Ras signaling pathway,3/6,0.16817401392563283,0.6802106630113267,2.201557935735151,CSF1_CSF1R;VEGFA_EGFR;FGF1_FGFR1,2,2,H1
33,gs_ind_0,Regulation of actin cytoskeleton,2/11,0.8154741575757216,0.9038933793810201,0.8400429414922168,CXCL12_CXCR4;FGF1_FGFR1,2,2,H1
34,gs_ind_0,Signaling by EGFR,1/1,0.25149700598802394,0.6802106630113267,4.0120481927710845,LRIG1_EGFR,2,2,H1
35,gs_ind_0,Signaling by ERBB2,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,HSP90AA1_EGFR,2,2,H1
36,gs_ind_0,Signaling by ERBB2 ECD mutants,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,HSP90AA1_EGFR,2,2,H1
37,gs_ind_0,Signaling by ERBB2 KD Mutants,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,HSP90AA1_EGFR,2,2,H1
38,gs_ind_0,Signaling by ERBB2 in Cancer,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,HSP90AA1_EGFR,2,2,H1
39,gs_ind_0,Signaling by NOTCH,3/7,0.2435269521510387,0.6802106630113267,1.8962025316455695,JAG1_NOTCH4;ADAM10_NOTCH1;ADAM10_NOTCH2,2,2,H1
40,gs_ind_0,Signaling by NOTCH1,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
41,gs_ind_0,Signaling by NOTCH1 HD Domain Mutants in Cancer,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
42,gs_ind_0,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
43,gs_ind_0,Signaling by NOTCH1 PEST Domain Mutants in Cancer,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
44,gs_ind_0,Signaling by NOTCH1 in Cancer,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
45,gs_ind_0,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,ADAM10_NOTCH1,2,2,H1
46,gs_ind_0,Signaling by NOTCH2,1/1,0.25149700598802394,0.6802106630113267,4.0120481927710845,ADAM10_NOTCH2,2,2,H1
47,gs_ind_0,Signaling by NOTCH4,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,JAG1_NOTCH4,2,2,H1
48,gs_ind_0,Small cell lung cancer,4/18,0.713094436661107,0.837110860428256,0.9445419445419445,LAMB1_ITGAV;LAMA4_ITGA6;LAMC1_ITGAV;LAMB1_ITGA6,2,2,H1
49,gs_ind_0,Th1 and Th2 cell differentiation,3/5,0.10187989887486598,0.6802106630113267,2.61795166858458,JAG2_NOTCH2;JAG2_NOTCH1;JAG1_NOTCH2,2,2,H1
50,gs_ind_0,Toxoplasmosis,2/8,0.6424265688817808,0.827929245561451,1.158315177923021,LAMA4_ITGA6;LAMB1_ITGA6,2,2,H1
51,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,4/19,0.7572702865474066,0.8700552228417012,0.8901098901098901,CCL28_CCR10;CSF1_CSF1R;CXCL12_CXCR4;IL34_CSF1R,2,2,H1
52,gs_ind_0,Wnt signaling pathway,1/2,0.4408772815814155,0.6802106630113267,2.3927710843373493,WNT7B_LRP5,2,2,H1
53,gs_ind_0,mTOR signaling pathway,1/3,0.5831994280879643,0.827929245561451,1.6987951807228916,WNT7B_LRP5,2,2,H1
0,gs_ind_0,Antigen processing and presentation,2/2,0.02344708174013419,0.4103239304523484,6.755102040816326,HLA-B_KLRD1;HLA-E_KLRD1,3,3,H1
1,gs_ind_0,Axon guidance,1/12,0.8784653802904292,0.931705706368637,0.731764705882353,SEMA4C_PLXNB2,3,3,H1
2,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,FN1_ITGA5,3,3,H1
3,gs_ind_0,Breast cancer,1/16,0.9421522442729354,0.9421522442729354,0.5401069518716578,JAG2_NOTCH2,3,3,H1
4,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.15568862275449102,0.4370772406815849,6.529411764705882,HSP90AA1_ERBB2,3,3,H1
5,gs_ind_0,ECM-receptor interaction,13/61,0.09283573960718355,0.4370772406815849,1.7317073170731707,TNC_SDC4;FN1_ITGB6;COL1A1_ITGAV;FN1_CD44;TNC_SDC1;COL4A1_ITGAV;TNC_ITGB6;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;TNC_ITGAV;FN1_ITGA5;COL4A5_ITGAV,3,3,H1
6,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/3,0.40013510765981725,0.5186936580775409,2.764705882352941,TGFA_ERBB2,3,3,H1
7,gs_ind_0,Endocrine resistance,1/12,0.8784653802904292,0.931705706368637,0.731764705882353,JAG2_NOTCH2,3,3,H1
8,gs_ind_0,Fibronectin matrix formation,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,FN1_ITGA5,3,3,H1
9,gs_ind_0,Focal adhesion,11/60,0.29971010789594393,0.4370772406815849,1.318315115969075,FN1_ITGB6;COL1A1_ITGAV;COL4A1_ITGAV;TNC_ITGB6;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;TNC_ITGA5;FN1_ITGA5;TNC_ITGAV;COL4A5_ITGAV,3,3,H1
10,gs_ind_0,Graft-versus-host disease,2/2,0.02344708174013419,0.4103239304523484,6.755102040816326,HLA-B_KLRD1;HLA-E_KLRD1,3,3,H1
11,gs_ind_0,Human papillomavirus infection,12/67,0.3183153584361139,0.44564150181055945,1.2835249042145593,FN1_ITGB6;COL1A1_ITGAV;COL4A1_ITGAV;TNC_ITGB6;MFNG_NOTCH2;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;TNC_ITGA5;FN1_ITGA5;TNC_ITGAV;COL4A5_ITGAV,3,3,H1
12,gs_ind_0,Leukocyte transendothelial migration,1/3,0.40013510765981725,0.5186936580775409,2.764705882352941,VCAM1_EZR,3,3,H1
13,gs_ind_0,MAPK signaling pathway,2/13,0.633827952229874,0.7394659442681863,1.1678004535147393,AREG_ERBB3;TGFA_ERBB2,3,3,H1
14,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.15568862275449102,0.4370772406815849,6.529411764705882,ADAM10_NOTCH2,3,3,H1
15,gs_ind_0,Natural killer cell mediated cytotoxicity,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,HLA-E_KLRD1,3,3,H1
16,gs_ind_0,Non-small cell lung cancer,1/1,0.15568862275449102,0.4370772406815849,6.529411764705882,TGFA_ERBB2,3,3,H1
17,gs_ind_0,Notch signaling pathway,2/16,0.751162828539135,0.8480870644796685,0.9369202226345084,JAG2_NOTCH2;MFNG_NOTCH2,3,3,H1
18,gs_ind_0,PI3K-Akt signaling pathway,13/68,0.20229485041250936,0.4370772406815849,1.4525547445255473,FN1_ITGB6;AREG_ERBB3;TGFA_ERBB2;COL1A1_ITGAV;COL4A1_ITGAV;TNC_ITGB6;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;TNC_ITGA5;FN1_ITGA5;TNC_ITGAV;COL4A5_ITGAV,3,3,H1
19,gs_ind_0,Pathways in cancer,4/41,0.92940399813526,0.9421522442729354,0.6096385542168675,JAG2_NOTCH2;COL4A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV,3,3,H1
20,gs_ind_0,Phospholipase D signaling pathway,1/1,0.15568862275449102,0.4370772406815849,6.529411764705882,ARF1_PLD2,3,3,H1
21,gs_ind_0,Pre-NOTCH Expression and Processing,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,MFNG_NOTCH2,3,3,H1
22,gs_ind_0,Pre-NOTCH Processing in Golgi,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,MFNG_NOTCH2,3,3,H1
23,gs_ind_0,Prostate cancer,1/1,0.15568862275449102,0.4370772406815849,6.529411764705882,TGFA_ERBB2,3,3,H1
24,gs_ind_0,Proteoglycans in cancer,3/10,0.18972257159019126,0.4370772406815849,2.234042553191489,FN1_SDC2;FN1_ITGAV;FN1_ITGA5,3,3,H1
25,gs_ind_0,Regulation of actin cytoskeleton,4/11,0.07101177233512278,0.4370772406815849,2.7217391304347824,FN1_ITGB6;FN1_ITGAV;FN1_ITGB7;FN1_ITGA5,3,3,H1
26,gs_ind_0,Signaling by ERBB2,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,HSP90AA1_ERBB2,3,3,H1
27,gs_ind_0,Signaling by ERBB2 ECD mutants,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,HSP90AA1_ERBB2,3,3,H1
28,gs_ind_0,Signaling by ERBB2 KD Mutants,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,HSP90AA1_ERBB2,3,3,H1
29,gs_ind_0,Signaling by ERBB2 in Cancer,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,HSP90AA1_ERBB2,3,3,H1
30,gs_ind_0,Signaling by NOTCH,2/7,0.29874022777447545,0.4370772406815849,2.183673469387755,ADAM10_NOTCH2;MFNG_NOTCH2,3,3,H1
31,gs_ind_0,Signaling by NOTCH2,1/1,0.15568862275449102,0.4370772406815849,6.529411764705882,ADAM10_NOTCH2,3,3,H1
32,gs_ind_0,Small cell lung cancer,3/18,0.5570113363859007,0.69487093099008,1.2035652673950545,COL4A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV,3,3,H1
33,gs_ind_0,Th1 and Th2 cell differentiation,1/5,0.5757501999632092,0.69487093099008,1.7379679144385027,JAG2_NOTCH2,3,3,H1
34,gs_ind_0,Yersinia infection,1/2,0.28793016376884784,0.4370772406815849,3.8941176470588235,FN1_ITGA5,3,3,H1
0,gs_ind_0,AGE-RAGE signaling pathway in diabetic complications,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,TGFB1_TGFBR2,4,4,H1
1,gs_ind_0,Antigen processing and presentation,2/2,0.02727075968544838,0.41815164851020853,6.245283018867925,HLA-B_KLRD1;HLA-E_KLRD1,4,4,H1
2,gs_ind_0,Axon guidance,3/12,0.32428229066034403,0.5737302065529164,1.707450980392157,EFNA1_EPHA4;CXCL12_CXCR4;SEMA4D_PLXNB2,4,4,H1
3,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,FN1_ITGA5,4,4,H1
4,gs_ind_0,Cell adhesion molecules,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,JAM3_ITGB2,4,4,H1
5,gs_ind_0,Cell adhesion molecules (CAMs),1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,JAM3_ITGB2,4,4,H1
6,gs_ind_0,Cellular senescence,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,TGFB1_TGFBR2,4,4,H1
7,gs_ind_0,Chemokine signaling pathway,8/16,0.0012070822141914542,0.0555257818528069,3.8070953436807096,CCL5_CXCR3;CXCL14_CXCR4;CXCL12_CXCR4;CCL19_CCR7;CXCL9_CXCR3;CCL21_CXCR3;CCL21_CCR7;CCL19_CXCR3,4,4,H1
8,gs_ind_0,Chronic myeloid leukemia,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,TGFB1_TGFBR2,4,4,H1
9,gs_ind_0,Cytokine-cytokine receptor interaction,6/29,0.3508408489288597,0.5977288537306498,1.3563088512241055,IL16_CD4;TGFB1_TGFBR2;CXCL12_CXCR4;CCL19_CCR7;CXCL9_CXCR3;CCL21_CCR7,4,4,H1
10,gs_ind_0,ECM-receptor interaction,10/61,0.6180697999592896,0.7290054050801877,0.982860909690178,COL1A2_CD44;COL1A1_ITGAV;FN1_CD44;COL4A1_ITGAV;COL1A2_ITGAV;COL1A1_CD44;FN1_ITGAV;FN1_ITGB7;FN1_ITGA5;COL4A5_ITGAV,4,4,H1
11,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/3,0.42547894353680366,0.6116259813341552,2.5636363636363635,TGFA_ERBB2,4,4,H1
12,gs_ind_0,Fibronectin matrix formation,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,FN1_ITGA5,4,4,H1
13,gs_ind_0,Focal adhesion,7/60,0.9408714916964461,0.9545774967695289,0.6198347107438017,COL1A1_ITGAV;COL4A1_ITGAV;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;FN1_ITGA5;COL4A5_ITGAV,4,4,H1
14,gs_ind_0,FoxO signaling pathway,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,TGFB1_TGFBR2,4,4,H1
15,gs_ind_0,Gastric cancer,1/4,0.5235679043963738,0.6519897483735592,1.981818181818182,TGFB1_TGFBR2,4,4,H1
16,gs_ind_0,Graft-versus-host disease,2/2,0.02727075968544838,0.41815164851020853,6.245283018867925,HLA-B_KLRD1;HLA-E_KLRD1,4,4,H1
17,gs_ind_0,Hepatitis B,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,TGFB1_TGFBR2,4,4,H1
18,gs_ind_0,Hepatocellular carcinoma,1/4,0.5235679043963738,0.6519897483735592,1.981818181818182,TGFB1_TGFBR2,4,4,H1
19,gs_ind_0,Hippo signaling pathway,1/3,0.42547894353680366,0.6116259813341552,2.5636363636363635,TGFB1_TGFBR2,4,4,H1
20,gs_ind_0,Human T-cell leukemia virus 1 infection,1/3,0.42547894353680366,0.6116259813341552,2.5636363636363635,TGFB1_TGFBR2,4,4,H1
21,gs_ind_0,Human cytomegalovirus infection,1/4,0.5235679043963738,0.6519897483735592,1.981818181818182,CXCL12_CXCR4,4,4,H1
22,gs_ind_0,Human papillomavirus infection,8/67,0.9449776404031173,0.9545774967695289,0.6173441734417344,COL1A1_ITGAV;COL4A1_ITGAV;MFNG_NOTCH2;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;FN1_ITGA5;COL4A5_ITGAV,4,4,H1
23,gs_ind_0,Intestinal immune network for IgA production,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,CXCL12_CXCR4,4,4,H1
24,gs_ind_0,Leukocyte transendothelial migration,2/3,0.07321785782214321,0.5668277902027271,4.433962264150943,CXCL12_CXCR4;JAM3_ITGB2,4,4,H1
25,gs_ind_0,MAPK signaling pathway,2/13,0.6779655510159767,0.7796603836683732,1.079664570230608,TGFB1_TGFBR2;TGFA_ERBB2,4,4,H1
26,gs_ind_0,Natural killer cell mediated cytotoxicity,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,HLA-E_KLRD1,4,4,H1
27,gs_ind_0,Non-small cell lung cancer,1/1,0.16766467065868262,0.5668277902027271,6.054545454545455,TGFA_ERBB2,4,4,H1
28,gs_ind_0,Notch signaling pathway,1/16,0.9545774967695289,0.9545774967695289,0.5008264462809917,MFNG_NOTCH2,4,4,H1
29,gs_ind_0,Osteoclast differentiation,1/3,0.42547894353680366,0.6116259813341552,2.5636363636363635,TGFB1_TGFBR2,4,4,H1
30,gs_ind_0,PI3K-Akt signaling pathway,8/68,0.9522482461757488,0.9545774967695289,0.6022787965105928,TGFA_ERBB2;COL1A1_ITGAV;COL4A1_ITGAV;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;FN1_ITGA5;COL4A5_ITGAV,4,4,H1
31,gs_ind_0,Pancreatic cancer,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,TGFB1_TGFBR2,4,4,H1
32,gs_ind_0,Pathways in cancer,5/41,0.8756534607278011,0.9545774967695289,0.7134068187644194,COL4A1_ITGAV;TGFB1_TGFBR2;CXCL12_CXCR4;FN1_ITGAV;COL4A5_ITGAV,4,4,H1
33,gs_ind_0,Pre-NOTCH Expression and Processing,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,MFNG_NOTCH2,4,4,H1
34,gs_ind_0,Pre-NOTCH Processing in Golgi,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,MFNG_NOTCH2,4,4,H1
35,gs_ind_0,Prostate cancer,1/1,0.16766467065868262,0.5668277902027271,6.054545454545455,TGFA_ERBB2,4,4,H1
36,gs_ind_0,Proteoglycans in cancer,2/10,0.5244265367352541,0.6519897483735592,1.4150943396226414,FN1_ITGAV;FN1_ITGA5,4,4,H1
37,gs_ind_0,Regulation of actin cytoskeleton,4/11,0.09017072712624441,0.5668277902027271,2.4995563442768414,CXCL12_CXCR4;FN1_ITGAV;FN1_ITGB7;FN1_ITGA5,4,4,H1
38,gs_ind_0,Relaxin signaling pathway,1/1,0.16766467065868262,0.5668277902027271,6.054545454545455,TGFB1_TGFBR2,4,4,H1
39,gs_ind_0,Signaling by NOTCH,1/7,0.7303734072626407,0.8194433349775969,1.1672727272727272,MFNG_NOTCH2,4,4,H1
40,gs_ind_0,Small cell lung cancer,3/18,0.6136259599381034,0.7290054050801877,1.1091679915209327,COL4A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV,4,4,H1
41,gs_ind_0,TGF-beta signaling pathway,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,TGFB1_TGFBR2,4,4,H1
42,gs_ind_0,Th17 cell differentiation,1/1,0.16766467065868262,0.5668277902027271,6.054545454545455,TGFB1_TGFBR2,4,4,H1
43,gs_ind_0,Tuberculosis,1/4,0.5235679043963738,0.6519897483735592,1.981818181818182,C3_ITGAX,4,4,H1
44,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,4/19,0.39775118791135167,0.6116259813341552,1.3987441130298273,CXCL9_CXCR3;CXCL12_CXCR4;CCL21_CCR7;CCL19_CCR7,4,4,H1
45,gs_ind_0,Yersinia infection,1/2,0.3080585816319169,0.5668277902027271,3.610909090909091,FN1_ITGA5,4,4,H1
0,gs_ind_0,ECM-receptor interaction,4/61,0.32383565381570223,0.39675817026302074,1.7317073170731707,COL6A2_ITGB1;LAMB2_ITGB1;COL6A2_ITGA1;COL1A1_ITGB1,5,5,H1
1,gs_ind_0,Focal adhesion,5/60,0.1115578110708713,0.2677387465700911,2.792207792207792,COL6A2_ITGB1;LAMB2_ITGB1;COL1A1_ITGA5;COL1A1_ITGB1;COL6A2_ITGA1,5,5,H1
2,gs_ind_0,Human papillomavirus infection,5/67,0.1698164926785839,0.2689740391715432,2.33968253968254,COL6A2_ITGB1;LAMB2_ITGB1;COL1A1_ITGA5;COL1A1_ITGB1;COL6A2_ITGA1,5,5,H1
3,gs_ind_0,Legionellosis,1/2,0.09378832696053674,0.2677387465700911,13.24,C3_ITGB2,5,5,H1
4,gs_ind_0,Leishmaniasis,1/2,0.09378832696053674,0.2677387465700911,13.24,C3_ITGB2,5,5,H1
5,gs_ind_0,PI3K-Akt signaling pathway,5/68,0.17931602611436215,0.2689740391715432,2.2825860271115745,COL6A2_ITGB1;LAMB2_ITGB1;COL1A1_ITGA5;COL1A1_ITGB1;COL6A2_ITGA1,5,5,H1
6,gs_ind_0,Pathways in cancer,1/41,0.9007615587645471,0.9007615587645471,0.6096385542168675,LAMB2_ITGB1,5,5,H1
7,gs_ind_0,Platelet activation,1/3,0.13772586262305622,0.2689740391715432,9.4,COL1A1_ITGB1,5,5,H1
8,gs_ind_0,Proteoglycans in cancer,2/10,0.07462951640111959,0.2677387465700911,5.769230769230769,HSPG2_ITGB1;COL1A1_ITGB1,5,5,H1
9,gs_ind_0,Small cell lung cancer,1/18,0.6067468396955636,0.6619056433042513,1.6162162162162161,LAMB2_ITGB1,5,5,H1
10,gs_ind_0,Toxoplasmosis,1/8,0.3306318085525173,0.39675817026302074,3.7529411764705882,LAMB2_ITGB1,5,5,H1
11,gs_ind_0,Tuberculosis,2/4,0.011539403494722949,0.1384728419366754,13.974358974358974,C3_ITGB2;C3_ITGAX,5,5,H1
0,gs_ind_0,Activated NOTCH1 Transmits Signal to the Nucleus,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
1,gs_ind_0,Adipocytokine signaling pathway,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,TNF_TNFRSF1A,6,6,H1
2,gs_ind_0,Amyotrophic lateral sclerosis (ALS),1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,TNF_TNFRSF1A,6,6,H1
3,gs_ind_0,Antigen processing and presentation,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,HLA-B_KLRD1,6,6,H1
4,gs_ind_0,Apoptosis,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,TNF_TNFRSF1A,6,6,H1
5,gs_ind_0,Axon guidance,3/12,0.6580858529669921,0.7897030235603905,1.0491566265060241,EFNB1_EPHB4;SEMA4D_PLXNB2;SEMA4C_PLXNB2,6,6,H1
6,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,FN1_ITGA5,6,6,H1
7,gs_ind_0,Breast cancer,2/16,0.9572796307102945,0.9943179804393003,0.5401069518716578,JAG2_NOTCH2;FGF4_FGFR1,6,6,H1
8,gs_ind_0,Chagas disease,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TNF_TNFRSF1A,6,6,H1
9,gs_ind_0,Chagas disease (American trypanosomiasis),1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TNF_TNFRSF1A,6,6,H1
10,gs_ind_0,Constitutive Signaling by NOTCH1 HD Domain Mutants,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
11,gs_ind_0,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
12,gs_ind_0,Constitutive Signaling by NOTCH1 PEST Domain Mutants,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
13,gs_ind_0,Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
14,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,HSP90AA1_ERBB2,6,6,H1
15,gs_ind_0,Cytokine-cytokine receptor interaction,5/29,0.9321900197977803,0.9870247268447085,0.6537223771722807,TNF_TNFRSF1A;INHA_ACVR2B;LTA_TNFRSF1A;LTB_LTBR;LTA_LTBR,6,6,H1
16,gs_ind_0,ECM-receptor interaction,18/61,0.2993523964338563,0.6880455955558763,1.208927749654855,TNC_SDC4;FN1_ITGB6;THBS1_SDC4;COL1A2_CD44;COL1A1_ITGAV;FN1_CD44;TNC_SDC1;COL4A1_ITGAV;FN1_ITGB8;TNC_ITGB6;LAMA5_ITGB4;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;TNC_ITGAV;FN1_ITGA5;COL4A5_ITGAV;COL1A2_ITGA11,6,6,H1
17,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/3,0.603044513382873,0.7359187281960484,1.6206896551724137,TGFA_ERBB2,6,6,H1
18,gs_ind_0,Endocrine resistance,1/12,0.9780555730209656,0.9943179804393003,0.4289655172413793,JAG2_NOTCH2,6,6,H1
19,gs_ind_0,Fibronectin matrix formation,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,FN1_ITGA5,6,6,H1
20,gs_ind_0,Focal adhesion,16/60,0.5416605260039768,0.7359187281960484,1.0287081339712918,FN1_ITGB6;COL1A1_ITGAV;COL4A1_ITGAV;VEGFA_EGFR;FN1_ITGB8;TNC_ITGB6;LAMA5_ITGB4;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;COL4A2_ITGB5;FN1_ITGA5;TNC_ITGA5;TNC_ITGAV;COL4A5_ITGAV;COL1A2_ITGA11,6,6,H1
21,gs_ind_0,Graft-versus-host disease,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,HLA-B_KLRD1,6,6,H1
22,gs_ind_0,Hepatitis C,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TNF_TNFRSF1A,6,6,H1
23,gs_ind_0,Herpes simplex virus 1 infection,1/3,0.603044513382873,0.7359187281960484,1.6206896551724137,TNF_TNFRSF1A,6,6,H1
24,gs_ind_0,Human T-cell leukemia virus 1 infection,1/3,0.603044513382873,0.7359187281960484,1.6206896551724137,TNF_TNFRSF1A,6,6,H1
25,gs_ind_0,Human cytomegalovirus infection,1/4,0.709544765889907,0.8239874700656984,1.2528735632183907,TNF_TNFRSF1A,6,6,H1
26,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.603044513382873,0.7359187281960484,1.6206896551724137,TNF_TNFRSF1A,6,6,H1
27,gs_ind_0,Human papillomavirus infection,16/67,0.7789849850022916,0.8864435922301308,0.8619883040935673,FN1_ITGB6;COL1A1_ITGAV;TNF_TNFRSF1A;COL4A1_ITGAV;FN1_ITGB8;TNC_ITGB6;LAMA5_ITGB4;COL1A2_ITGAV;FN1_ITGAV;FN1_ITGB7;COL4A2_ITGB5;FN1_ITGA5;TNC_ITGA5;TNC_ITGAV;COL4A5_ITGAV;COL1A2_ITGA11,6,6,H1
28,gs_ind_0,Insulin resistance,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TNF_TNFRSF1A,6,6,H1
29,gs_ind_0,Leukocyte transendothelial migration,1/3,0.603044513382873,0.7359187281960484,1.6206896551724137,VCAM1_EZR,6,6,H1
30,gs_ind_0,MAPK signaling pathway,6/13,0.09081937220360246,0.6880455955558763,1.9321789321789322,AREG_ERBB3;TGFA_ERBB2;TNF_TNFRSF1A;VEGFA_EGFR;FGF4_FGFR4;FGF4_FGFR1,6,6,H1
31,gs_ind_0,Melanoma,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,FGF4_FGFR1,6,6,H1
32,gs_ind_0,NF-kappa B signaling pathway,3/4,0.05646057283024312,0.6880455955558763,3.0642570281124497,LTA_LTBR;TNF_TNFRSF1A;LTB_LTBR,6,6,H1
33,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,ADAM10_NOTCH2,6,6,H1
34,gs_ind_0,Necroptosis,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,TNF_TNFRSF1A,6,6,H1
35,gs_ind_0,Non-alcoholic fatty liver disease,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TNF_TNFRSF1A,6,6,H1
36,gs_ind_0,Non-alcoholic fatty liver disease (NAFLD),1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TNF_TNFRSF1A,6,6,H1
37,gs_ind_0,Non-small cell lung cancer,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TGFA_ERBB2,6,6,H1
38,gs_ind_0,Notch signaling pathway,1/16,0.9943179804393003,0.9943179804393003,0.3166144200626959,JAG2_NOTCH2,6,6,H1
39,gs_ind_0,Osteoclast differentiation,1/3,0.603044513382873,0.7359187281960484,1.6206896551724137,TNF_TNFRSF1A,6,6,H1
40,gs_ind_0,PI3K-Akt signaling pathway,20/68,0.28453065800491356,0.6880455955558763,1.2154029495009682,FN1_ITGB6;COL4A1_ITGAV;VEGFA_EGFR;FGF4_FGFR4;FN1_ITGB7;FGF4_FGFR1;AREG_ERBB3;COL1A1_ITGAV;FN1_ITGB8;COL1A2_ITGAV;FN1_ITGA5;FN1_ITGAV;TGFA_ERBB2;TNC_ITGB6;LAMA5_ITGB4;COL4A2_ITGB5;TNC_ITGA5;TNC_ITGAV;COL4A5_ITGAV;COL1A2_ITGA11,6,6,H1
41,gs_ind_0,Pathogenic Escherichia coli infection,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,TNF_TNFRSF1A,6,6,H1
42,gs_ind_0,Pathways in cancer,6/41,0.987836336032618,0.9943179804393003,0.5146299483648882,JAG2_NOTCH2;COL4A1_ITGAV;FGF4_FGFR4;FN1_ITGAV;COL4A5_ITGAV;FGF4_FGFR1,6,6,H1
43,gs_ind_0,Phospholipase D signaling pathway,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,ARF1_PLD2,6,6,H1
44,gs_ind_0,Prostate cancer,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TGFA_ERBB2,6,6,H1
45,gs_ind_0,Proteoglycans in cancer,3/10,0.5178322303078151,0.7359187281960484,1.2650602409638554,FN1_SDC2;FN1_ITGAV;FN1_ITGA5,6,6,H1
46,gs_ind_0,Rap1 signaling pathway,3/6,0.18781210421036687,0.6880455955558763,2.0954587581093604,VEGFA_EGFR;FGF4_FGFR4;FGF4_FGFR1,6,6,H1
47,gs_ind_0,Ras signaling pathway,3/6,0.18781210421036687,0.6880455955558763,2.0954587581093604,VEGFA_EGFR;FGF4_FGFR4;FGF4_FGFR1,6,6,H1
48,gs_ind_0,Regulation of actin cytoskeleton,7/11,0.008075528910795955,0.5814380815773088,2.7217391304347824,FN1_ITGB6;FN1_ITGB8;FGF4_FGFR4;FN1_ITGAV;FN1_ITGB7;FN1_ITGA5;FGF4_FGFR1,6,6,H1
49,gs_ind_0,Signaling by EGFR,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,LRIG1_EGFR,6,6,H1
50,gs_ind_0,Signaling by ERBB2,2/2,0.06824904408051366,0.6880455955558763,3.8941176470588235,HSP90AA1_ERBB2;HSP90AA1_EGFR,6,6,H1
51,gs_ind_0,Signaling by ERBB2 ECD mutants,2/2,0.06824904408051366,0.6880455955558763,3.8941176470588235,HSP90AA1_ERBB2;HSP90AA1_EGFR,6,6,H1
52,gs_ind_0,Signaling by ERBB2 KD Mutants,2/2,0.06824904408051366,0.6880455955558763,3.8941176470588235,HSP90AA1_ERBB2;HSP90AA1_EGFR,6,6,H1
53,gs_ind_0,Signaling by ERBB2 in Cancer,2/2,0.06824904408051366,0.6880455955558763,3.8941176470588235,HSP90AA1_ERBB2;HSP90AA1_EGFR,6,6,H1
54,gs_ind_0,Signaling by NOTCH,2/7,0.5922738082574122,0.7359187281960484,1.2588235294117647,ADAM10_NOTCH1;ADAM10_NOTCH2,6,6,H1
55,gs_ind_0,Signaling by NOTCH1,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
56,gs_ind_0,Signaling by NOTCH1 HD Domain Mutants in Cancer,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
57,gs_ind_0,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
58,gs_ind_0,Signaling by NOTCH1 PEST Domain Mutants in Cancer,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
59,gs_ind_0,Signaling by NOTCH1 in Cancer,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
60,gs_ind_0,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,ADAM10_NOTCH1,6,6,H1
61,gs_ind_0,Signaling by NOTCH2,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,ADAM10_NOTCH2,6,6,H1
62,gs_ind_0,Small cell lung cancer,3/18,0.9032772262312356,0.9870247268447085,0.6815369586453924,COL4A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV,6,6,H1
63,gs_ind_0,Sphingolipid signaling pathway,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TNF_TNFRSF1A,6,6,H1
64,gs_ind_0,TNF signaling pathway,1/3,0.603044513382873,0.7359187281960484,1.6206896551724137,TNF_TNFRSF1A,6,6,H1
65,gs_ind_0,TNFR2 non-canonical NF-kB pathway,1/1,0.26347305389221554,0.6880455955558763,3.8275862068965516,TNF_TRAF2,6,6,H1
66,gs_ind_0,Th1 and Th2 cell differentiation,1/5,0.7879498597601162,0.8864435922301308,1.0188087774294672,JAG2_NOTCH2,6,6,H1
67,gs_ind_0,Toxoplasmosis,1/8,0.9186226489069058,0.9870247268447085,0.6470588235294118,TNF_TNFRSF1A,6,6,H1
68,gs_ind_0,Tuberculosis,1/4,0.709544765889907,0.8239874700656984,1.2528735632183907,TNF_TNFRSF1A,6,6,H1
69,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,3/19,0.9237468614336389,0.9870247268447085,0.6422613531047267,LTA_LTBR;TNF_TNFRSF1A;LTA_TNFRSF1A,6,6,H1
70,gs_ind_0,Yersinia infection,1/2,0.4586970637039175,0.6880455955558763,2.282758620689655,FN1_ITGA5,6,6,H1
71,gs_ind_0,mTOR signaling pathway,1/3,0.603044513382873,0.7359187281960484,1.6206896551724137,TNF_TNFRSF1A,6,6,H1
